



# LUND UNIVERSITY

## Novel Endogenous Antimicrobial Peptides

Nordahl, Emma

2009

[Link to publication](#)

*Citation for published version (APA):*

Nordahl, E. (2009). *Novel Endogenous Antimicrobial Peptides*. [Doctoral Thesis (compilation), Dermatology and Venereology (Lund)]. Department of Clinical Sciences, Lund University.

*Total number of authors:*

1

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

# NOVEL ENDOGENOUS ANTIMICROBIAL PEPTIDES

**Emma Andersson Nordahl**

Institutionen för kliniska vetenskaper, Lund  
Avdelningen för dermatologi och venereologi,  
Lunds universitet

## **Akademisk avhandling**

som med vederbörligt tillstånd från medicinska fakulteten  
vid Lunds universitet för avläggande av doktorexamen i  
medicinsk vetenskap, kommer att offentligen försvaras  
i Belfragesalen D15, Biomedicinskt centrum, Sölvegatan 19,  
tisdagen den 19 maj 2009 kl. 9.15


## **Fakultetsopponent**

**Professor Dan Hultmark**  
Institutionen för molekylärbiologi,  
Umeå universitet

Organization LUND UNIVERSITY		Document name DOCTORAL DISSERTATION	
Department of Clinical Sciences, Lund Section of Dermatology and Venereology BMC B14 Tornavägen 10, 221 84, Lund		Date of issue May 19, 2009	
		Sponsoring organization	
Author(s) Emma Andersson Nordahl			
Title and subtitle Novel Endogenous Antimicrobial Peptides			
Abstract  Antimicrobial peptides serve as a first line of defence against invading microorganisms and are an essential part of our fast innate immune system. They are ancient molecules found in all classes of life. Antimicrobial peptides rapidly kill a broad spectrum of microbes and are immunomodulatory, i.e. having additional actions influencing inflammation and other innate immune responses. Results presented in this thesis demonstrate that proteases of common human pathogens degrade and inactivate the antimicrobial peptide LL-37, probably a strategy for bacteria to circumvent the action of antimicrobial peptides. Likewise, heavily sulphated glycosaminoglycans like dermatan sulphate and heparin were shown to bind to and inactivate LL-37. Furthermore, we demonstrate that structural characteristics associated with heparin affinity (cationicity and amphipathicity) may confer antimicrobial properties to any given peptide. Heparin-binding consensus sequences were proven to be active against Gram-positive bacteria, Gram-negative bacteria and the fungus <i>Candida albicans</i> . Similar results were obtained with synthetic peptides derived from heparinbinding sequences within endogenous proteins. In addition, novel antimicrobial activity and heparin-binding capacity were discovered for the anaphylatoxin C3a, generated during activation of the complement system, and the inactive derivative of C3a (C3a <sub>desArg</sub> ), as well as shorter synthetic peptides from the molecule. Novel antimicrobial activity was also shown for the heparin-binding and cell-binding domain 5 of high molecular weight kininogen, a substrate in the intrinsic pathway of coagulation. Interestingly, the peptide HKH20 (His <sup>479</sup> -His <sup>498</sup> ) from this domain was active in high salt, and highly resistant to degradation by various bacterial proteases. The understanding that heparin binding is a property of many antimicrobial peptides may represent a powerful tool in the discovery of novel endogenous antimicrobial peptides from complex biological mixtures.			
Key words: Antimicrobial peptide, AMP, antibacterial, heparin-binding, complement, C3a, HMWK, HK, D5			
Classification system and/or index terms (if any):			
Supplementary bibliographical information:		Language English	
ISSN and key title: 1652-8220		ISBN 978-91-86253-39-4	
Recipient's notes		Number of pages 136	Price
		Security classification	

Distribution by (name and address): Emma Andersson Nordahl, BMC B14, Tornavägen 10, 221 84, Lund  
I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature



Date March 30, 2009

# NOVEL ENDOGENOUS ANTIMICROBIAL PEPTIDES

**Emma Andersson Nordahl**

---

Department of Clinical Sciences, Lund  
Section of Dermatology and Venereology,  
Lund University



**LUND UNIVERSITY**  
Faculty of Medicine

**Lund 2009**

Emma Andersson Nordahl

Phone: +46 (0)736 00 12 34

Fax: +46 (0)40 41 09 21

E-mail: emma.nordahl@nykraft.nu

Front image: Electron micrograph of *Pseudomonas aeruginosa* bacteria (upper left) subjected to C3 (lower left), C3a (upper right) and C3a<sub>desArg</sub> (lower right).

Photo by Dr. Matthias Mörgelin.

Back: Photo by Joi Grinde

Printed by Media-Tryck, Lund University, Sweden

© Emma Andersson Nordahl, 2009

© Blackwell publishing Ltd

© National Academy of Sciences

© American Society for Biochemistry and Molecular Biology

ISSN 1652-8220

ISBN 978-91-86253-39-4

Lund University, Faculty of Medicine Doctoral Dissertation Series 2009:51

**With love to my  
angel baby girl Isa**



**ABSTRACT**

Antimicrobial peptides serve as a first line of defence against invading microorganisms and are an essential part of our fast innate immune system. They are ancient molecules found in all classes of life. Antimicrobial peptides rapidly kill a broad spectrum of microbes and are immunomodulatory, i.e. having additional actions influencing inflammation and other innate immune responses. Results presented in this thesis demonstrate that proteases of common human pathogens degrade and inactivate the antimicrobial peptide LL-37, probably a strategy for bacteria to circumvent the action of antimicrobial peptides. Likewise, heavily sulphated glycosaminoglycans like dermatan sulphate and heparin were shown to bind to and inactivate LL-37. Furthermore, we demonstrate that structural characteristics associated with heparin affinity (cationicity and amphipathicity) may confer antimicrobial properties to any given peptide. Heparin-binding consensus sequences were proven to be active against Gram-positive bacteria, Gram-negative bacteria and the fungus *Candida albicans*. Similar results were obtained with synthetic peptides derived from heparin-binding sequences within endogenous proteins. In addition, novel antimicrobial activity and heparin-binding capacity were discovered for the anaphylatoxin C3a, generated during activation of the complement system, and the inactive derivative of C3a (C3a<sub>desArg</sub>), as well as shorter synthetic peptides from the molecule. Novel antimicrobial activity was also shown for the heparin-binding and cell-binding domain 5 of high molecular weight kininogen, a substrate in the intrinsic pathway of coagulation. Interestingly, the peptide HKH20 (His<sup>479</sup>-His<sup>498</sup>) from this domain was active in high salt, and highly resistant to degradation by various bacterial proteases. The understanding that heparin binding is a property of many antimicrobial peptides may represent a powerful tool in the discovery of novel endogenous antimicrobial peptides from complex biological mixtures.





## TABLE OF CONTENTS

ABSTRACT .....	7
ABBREVIATIONS .....	11
LIST OF PAPERS .....	13
PREFACE .....	15
My Personal Aspect of Life Science .....	15
INTRODUCTION .....	17
BACKGROUND .....	17
SKIN EPITHELIUM .....	18
Anatomy .....	19
Wound Healing .....	22
IMMUNE SYSTEMS .....	25
An Overview .....	25
Innate Immunity .....	26
ANTIMICROBIAL PEPTIDES .....	30
Structure .....	33
Main Families .....	37
Mode of Action .....	42
Bacterial Resistance Strategies .....	48
Antimicrobial Proteins .....	49
Antimicrobial Defences of the Skin .....	51
Antimicrobial Peptides in Clinical Medicine .....	52
PRESENT INVESTIGATION .....	57
AIMS OF THE THESIS .....	57
RESULTS AND DISCUSSION .....	58
Paper I .....	58
Paper II .....	59
Paper III .....	61
Paper IV .....	62
CONCLUSIONS .....	64
CONCLUDING REMARKS .....	65
POPULÄRVETENSKAPLIG SAMMANFATTNING (IN SWEDISH) .....	67
ACKNOWLEDGEMENTS .....	73
REFERENCES .....	77
APPENDIX (PAPER I - IV) .....	93



**ABBREVIATIONS**

AMP	antimicrobial peptide
BK	bradykinin
BPI	bactericidal/permeability-increasing protein
C3, 4, 5	complement factor 3 - 5
<i>CAMP</i>	cathelicidin antimicrobial peptide
CRAMP	cathelin-related antimicrobial peptide
CS	chondroitin sulphate
D3, 5	domain 3, 5
DS	dermatan sulphate
ECM	extracellular matrix
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
FIC	fractional inhibitory concentration
FPRL1	formyl peptide receptor-like 1
GAG	glycosaminoglycan
HBP	heparin-binding protein
hBD-1, 2, 3, 4	human $\beta$ -defensin 1 - 4
hCAP-18	human cationic antimicrobial protein-18
HD-5, 6	human defensin 5, 6 ( $\alpha$ -defensins)
HDP	host defence peptide
HMWK	high molecular weight kininogen
HNP-1, 2, 3, 4	human neutrophil peptide 1 - 4 ( $\alpha$ -defensins)
HRG	histidine-rich glycoprotein
LBP	lipopolysaccharide binding protein
LPS	lipopolysaccharide
LTA	lipoteichoic acid
MAC	membrane attack complex

MASP	mannose binding lectin-associated serine protease
MBL	mannose binding lectin
MEC	minimal effective concentration
MHC	major histocompatibility complex
MIC	minimal inhibitory concentration
PAMPs	pathogen associated molecular patterns
PDGF	platelet-derived growth factor
PMN	polymorphonuclear leukocytes (neutrophils)
PRRs	pattern recognition receptor
rD5	recombinant domain 5
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
SLPI	secretory leukoprotease inhibitor
TGF	transforming growth factor
TLR	toll-like receptor

## LIST OF PAPERS

This thesis is based on the following papers, which will be referred to in the text by their roman numerals (I - IV):

- I. Artur Schmidtchen, Inga-Maria Frick, **Emma Andersson**, Hans Tapper and Lars Björck (2002). Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Molecular Microbiology* **46**, 157-168.
- II. **Emma Andersson**, Victoria Rydengård, Andreas Sonesson, Matthias Mörgelin, Lars Björck and Artur Schmidtchen (2004). Antimicrobial activities of heparin-binding peptides. *European Journal of Biochemistry* **271**, 1219-1226.
- III. **Emma Andersson Nordahl**, Victoria Rydengård, Patrik Nyberg, D. Patric Nitsche, Matthias Mörgelin, Martin Malmsten, Lars Björck, and Artur Schmidtchen (2004). Activation of the complement system generates antibacterial peptides. *Proceedings of the National Academy of Sciences U S A* **101**, 16879-16884.
- IV. **Emma Andersson Nordahl**, Victoria Rydengård, Matthias Mörgelin, and Artur Schmidtchen (2005). Domain 5 from high molecular weight kininogen is antibacterial. *The Journal of Biological Chemistry* **280**, 34832-34839.



## **PREFACE**

### **My Personal Aspect of Life Science**

*During my Masters, I studied antibiotic resistance in a common human pathogen, Streptococcus pyogenes. I noticed that resistance against conventional antibiotics was easily developed. Without treatment these bacteria may cause severe infections in the host like strep throat, scarlet fever and acute rheumatic fever. Invasive infections may result in streptococcal toxic shock syndrome. Since antibiotic resistance among a wide range of bacteria is increasing at an alarming rate, society urgently needs to find new ways to combat these microbes.*

*During a project, I came across the interesting and fascinating field of antimicrobial peptides. These ancient peptides, found in all classes of life, are known to be important agents in the first line of defence against invading bacteria. What is their mode of action? May antimicrobial peptides be a solution in the efforts to find new approaches to fight pathogenic bacteria and fungi? Is it possible to design drugs based on the principles of these peptides?*

*In 2002, I got the opportunity to start my PhD-studies in the Artur Schmidtchen group at the section of dermatology, Lund University. About the same time his research was entering the world of antimicrobial peptides and I felt fortunate to start working with the group at such an early stage in this field of research. The main question we wanted to answer was – Why do most wounds stay free from all surrounding bacteria and heal, whereas some wounds, especially among elderly people and diabetes patients become extensively colonized with several types of bacteria and are not able to heal?*

*Bacterial proteases common in chronic wounds were found to degrade the AMP, LL-37 (paper I). In the same study we also realized that LL-37 is bound to and inactivated by disaccharides like heparin and dermatan sulphate. My PhD-research then continued to focus on using the heparin-binding capacity of AMPs to find novel ones. We discovered that many AMPs may be produced via degradations of different plasma proteins during normal wound healing (paper II, IV), with probably a key role in keeping the acute wound clean and free from microbes. Importantly, we also found that potent AMPs are made during activation of the complement system (paper III).*



*The 11<sup>th</sup> of July 2005 my daughter, Isa, was borne. I went on parental leave thinking that this will be a nice break from my PhD-studies. Isa was a gorgeous and happy child and we had a wonderful time together. When she was four months of age the most terrible thing came into our lives. Isa was diagnosed with infant acute lymphatic leukaemia. Our entire world was completely destroyed. Ten months of treatments and hospital care ended when Isa died on the 16<sup>th</sup> of September 2006. My husband and I went from the greatest happiness to the deepest of sorrows in a moment. Importantly, Isa taught me some essential things about life that I will always bear with me; the importance of a positive attitude to life, a bearable philosophy, and the importance of believing in the beauty and joy of tomorrow to be able to live fully today.*

*Nowadays, I often think about this in connection with medical science. In our western society medical science has sometimes become more of a religion. Clinical doctors keep trying to decide about life and death, even if they almost never succeed in this. It is important to see that unexpected situations appear all the time, both positive and negative ones. Personally, I do not think that it is beneficial for anybody to portray the worst scenario in a clinical situation and to let children and families feel terrible about things that may never occur? In real life, we all have to deal with the things that actually occur anyway, so what is the point of taking the worst thing, including sorrows and anxiety, out in advance.*

*As researchers, we must all remember that we do not have all the answers. Why not, in concert with medical science, use the most powerful tool we all have - the strength of our positive thoughts and feelings? I think it must be easier for everybody involved to give people strength, hope, and fighting spirit, rather than doing the opposite. Is it not inhibitive for research to believe that we have the only solution to a problem, especially if we do not completely understand the background of it? It is very important to do research and to try to find answers, but also to be humble to the fact that the answer might be of an entirely different kind than we have first imagined. I am completely sure that we will get even better clinical results if we allow ourselves to believe in the strength of the individual and support those who want to and have decided to feel good and to be well.*



## INTRODUCTION

### Background

Rapid defence mechanisms are essential to prevent invasion and colonization by pathogens in response to a disrupted barrier, such as a mucosal layer or the skin. This defence is promoted by cooperations between the fast innate and the slower adaptive immune systems. The recognition of microbes by innate immunity is mainly due to binding of pathogen-associated molecular patterns (PAMPs), such as polysaccharides and peptidoglycans, by Toll-like receptors (TLRs) on either plasma cells or epithelial cells. This sensing is followed by an efficient killing of microorganisms by recruitment of inflammatory leukocytes or local synthesis of bactericidal substances by epithelial cells. In either scenario, the response includes mobilization and/or production of antimicrobial peptides (AMPs). As part of innate immunity, AMPs contribute to an important first line of defence against invading microorganisms. They provide a rapid and non-specific response.

AMPs produced by bacteria are called bacteriocins and are classified into two groups, based on the inclusion or exclusion of an unusual amino acid called lanthionine. The bacteria *Lactococcus lactis* produce a lantibiotic called, nisin, to combat other surrounding microbes. Nisin was actually one of the first AMPs to be recognized<sup>1</sup>. Nisin is extremely potent in action against different Gram-positive bacteria with minimal inhibitory concentrations (MICs) at only nanomolar amounts. Without any significant development of resistance, nisin has been commonly used for over 50 years as a food preservative.

As early as the mid fifties, Hirsch<sup>2,3</sup> presented evidence for bactericidal substances in extracts from phagocytic granules of rabbit polymorphonuclear leukocytes (PMN). Seven years later, this finding was correlated with the discovery of Zeya and Spitznagel, who identified antimicrobial activity in cationic proteins from rabbit neutrophilic lysosomes<sup>4,6</sup>. However, these peptides were not successfully purified

---

until 1984<sup>7</sup>. In 1975, bactericidal/permeability-increasing protein was identified and purified from rabbit granulocytes<sup>8</sup> and the same year it was shown that a number of different cationic proteins are responsible for the oxygen independent, heat stable killing of bacteria in human polymorphonuclear leukocytes<sup>9</sup>. Some of these cationic peptides were eventually isolated, characterized, and named defensins<sup>10</sup>.

The AMP group was however first properly described in the silk moth, *Hyalophora cecropia*, in the early seventies by Hans G. Boman and associates. The immune system of this insect was investigated by injecting bacteria in the *cecropia* pupae and isolating the hemolymph. After several years of hard work, the primary structures of the first two AMPs were reported, cecropin A and B<sup>11</sup>. This field of research expanded further with Michael Zasloff's discovery and isolation of two potent AMPs (magainins) from the skin of the African clawed frog *Xenopus laevis*<sup>12</sup>.

Today we know that all multicellular organisms, thus far investigated, express a blend of AMPs which are distributed at biological boundaries likely to be exposed to the surrounding microflora<sup>13-16</sup>. In higher animals AMPs are produced both locally in epithelial cells, and systemically carried in granules of myeloid cells. They are both inducibly and constitutively expressed, depending on the site of expression<sup>17</sup>.

## **Skin Epithelium**

The skin accounts for approximately 16% of the total weight of the human body and is thereby our largest organ. It presents a physical, chemical, as well as an immunological barrier to infection, and displays a substantial innate immune capacity, including AMPs and antimicrobial proteins<sup>18</sup>. Other important functions include gas exchange, nutrient absorption, water conservation, regulation of body temperature, and synthesis of vitamin D<sup>19</sup>.

## Anatomy

Two different layers of the skin are defined and they are collectively called the cutis. The outer layer is epithelial and of ectodermal embryonic origin, called the epidermis. The epidermis is attached to and supported by connective tissue in the mesenchymal dermis, of mesodermal origin. Beneath the dermis is the subcutis or hypodermis. This region is rich in adipose tissue (fat) as an energy reservoir.


The skin is often exposed to harmful assaults like ultraviolet radiation from the sun, scratches, and wounds. It is therefore important for the epidermis to be able to constantly undergo renewal to replace old cells and repair tissue damage. This renewal is dependent on keratinocyte stem cells found in the lower epidermis and is performed by the process of homeostasis<sup>20</sup>.

### *The Epidermis*

The thickness of the epidermis averages 0.1 mm, with only 0.02 mm on the face and up to 1 - 5 mm on the soles of the feet. Despite the thin nature of the epidermis it is composed of many layers of cells and it is subdivided into five strata (figure 1).

The keratinocyte is the predominant cell type within the epidermis. These cells gradually move from the basal layer towards the surface of the skin. During the migration, the cells change shape, composition, and become filled with keratins, the major structural proteins of skin, hair, and nails. The terminal differentiation, called keratinization, takes place at the granular layer and the cells transform into flat horny skin cells called corneocytes, where the cytoplasm of the cells have disappeared and the nuclei have been digested. The *Stratum corneum* corneocytes are dead cells that provide an impenetrable physical barrier that protects the underlying viable layers. This barrier is continuously replenished as inner layers migrate outwards, and dead cells are sloughed off from the skin surface<sup>19</sup>.

Lipids of glucosyl ceramides, cholesterol, cholesterol esters, and long-chain fatty acids are released by lamellar bodies (keratinosomes) of keratinocytes in *Stratum granulosum* into the intercellular space as the *Stratum corneum* is formed. The lipids form multiple layers between the corneocytes. This lipid “mortar” is important for the barrier function of the skin, and the fatty acids contained may be necessary for the acidic pH (4 to 5.5) at the surface of the skin<sup>19,21</sup>. The lamellar bodies have also been described to release the AMP human  $\beta$ -defensin-2 (hBD-2) into the intercorneocyte space<sup>22</sup>.



**Figure 1.** Schematic drawing of the layered epidermis of human skin.


Other important cell types within the epidermis are the pigment producing melanocytes, the dendritic immune cells of the skin and mucosa, (Langerhans cells), and the basal Merkel cells. Melanin is the pigment of skin and hair produced by melanosomes in the melanocytes. Melanosomes are transferred to dividing keratinocytes at the basal layer and melanin serves to protect the nuclei from damaging UV-radiation. The Langerhans cells are important mediators in adaptive

immunity and are found in all layers of epidermis. In response to infection local Langerhans' cells will take up and process microbial antigens to become functional antigen-presenting cells<sup>19</sup>. Merkel cells are oval cells found in the *Stratum basale*. Their precise function is still unclear, but they are associated with the sense of touch and with sensory nerve endings.

### *The Dermis*

The dermis is divided into two functional layers, papillary dermis and reticular dermis. The papillary zone is found closest beneath the *Basal lamina* with a depth of between 0.3-0.4 mm, depending on factors like age and anatomical location. The papillary region contains a vascular network to serve the avascular epidermis with nutrients and to regulate body temperature. In sensitive skin areas there are free sensory nerve endings, such as Meissners corpuscles. In the papillary dermis the collagen fibre bundles are thin and poorly organized<sup>23</sup>. The reticular dermis, located beneath the papillary region, is built up by dense connective tissue to give the skin elasticity and strength. It contains well-organized fibre bundles of thick collagen, the elastic protein elastin, and proteoglycans. These are all secreted by fibroblasts, the most common cell type of the dermis. The reticular dermis also houses hair follicles, sweat glands, and sebaceous glands<sup>23</sup>.

Proteoglycans are heavily glycosylated glycoproteins with a core protein and one or more covalently attached glycosaminoglycan (GAG) chains. These GAG-chains are long and linear carbohydrate polymers, with a negative charge under physiological condition, due to sulphate and uronic acid side groups. Dermatan sulphate (DS), previously called chondroitin sulphate-B (CS-B), and heparan sulphate (HS) are two GAGs found in dermis proteoglycans. Heparin is a member of the heparan sulphate family of complex sugars and is released from mast cells at sites of tissue injury. The interesting findings that these GAGs bind and inactivate the cationic AMPs,  $\alpha$ -defensin (HNP-1)<sup>24</sup> and LL-37<sup>25</sup>, were the starting point of the work for this thesis.



**Figure 2.** Chemical structures of single units of two glycosaminoglycans (GAGs) found in the human dermis (A) Dermatan sulphate (DS) and (B) Heparan sulphate (HS). This compared with a single unit of (C) the heparin molecule found in and released from mast cells.

## Wound Healing

Wound healing is a complex and dynamic process whereby the body regenerates itself and repair tissue damage. The process requires cooperation of a number of different cell types, such as platelets, different leukocytes, and ultimately fibroblasts and keratinocytes. Wound healing encompasses three overlapping phases including inflammation, proliferation, and tissue remodelling.

### *Inflammatory Phase*

Tissue injury causes disruption of blood vessels and blood constituents are released into the wounded area. Platelets aggregate to form the primary hemostatic plug. In order to stop extensive blood loss, platelets stimulate activation of plasma coagulation factors. Prothrombin is activated to thrombin which then converts fibrinogen to fibrin to generate a stable clot of fibrin, fibronectin and the GAG hyaluronic acid<sup>26</sup>. This clot serves as a provisional extracellular matrix (ECM). It protects the wound and is the main structural support until collagen fibres are restored in the area.

Aggregated thrombocytes are triggered to stimulate an inflammatory response. They secrete potent chemoattractants for inflammatory cells, such as platelet-derived growth factor (PDGF) and transforming growth factor- $\beta$  (TGF- $\beta$ )<sup>27</sup>, factors that activates local fibroblasts and endothelial cells and vasoconstrictors<sup>28</sup>.

The inflammatory phase is characterized by a massive degradation of injured ECM components. Neutrophils clean the wound from bacteria, and macrophages phagocytose matrix and cell debris, including consumed neutrophils. Monocytes and macrophages are essential during repair, both in cleaning the wound from debris, but also in the production of growth factors necessary for matrix formation and angiogenesis (TGF- $\alpha$ , TGF- $\beta$  and interleukin-1), making these cells important in the transition between inflammation and tissue re-epithelialization during wound healing<sup>26</sup>. The absence of macrophages significantly impairs wound healing<sup>29</sup>.

### *Proliferative Phase*

The proliferative phase is characterized by activation of local fibroblasts, granulation, contraction, and epithelialization.

Growth factors, particularly PDGF and TGF- $\beta$ 1, together with ECM molecules stimulate fibroblasts at the wound margin to express integrin receptors, to proliferate and to migrate over the provisional ECM in the wounded area. Fibroblasts begin to enter the wound area about two or three days after injury, and this migration marks the start of the proliferative phase, even before the inflammatory phase has ended. In three to five days, these cells will become the predominant cell type in non-infected wounds.

Fibroblasts are responsible for ECM materials like collagen (type I and III), fibronectin, and proteoglycans to be deposited in the area and thereby the provisional matrix is gradually replaced by a collagenous ECM. Angiogenesis, which provides the area with nutrients and oxygen, fibroblast proliferation, and the



expression of the appropriate integrin receptors that bind fibronectin and fibrin, are essential steps in the formation of granulation tissue (new stroma)<sup>26,29</sup>.

Wound contraction is a phenomenon in which the marginal skin is pulled toward the wound. About a week after the injury, fibroblasts start to differentiate into myofibroblasts and the wound begins to contract. Myofibroblasts are responsible for contraction and they contain the same kind of actin as in smooth muscle cells. Actin is linked across the cell membrane to fibronectin and collagen in the ECM. When the actin in myofibroblasts contracts the wound edges are pulled together. The contraction stage ends when myofibroblasts stop contracting and go into apoptosis<sup>30</sup>. Without any new formation of tissue, the contraction process dramatically decreases the size of the wound and speeds up the closure of the wound resulting in a smaller scar than that by epithelialization alone<sup>28</sup>.

During epithelialization, keratinocytes migrate across the wound to re-establish the epidermis. Formation of actin filaments and pseudopodia makes keratinocytes able to move from the basal membrane at the edge of the wound<sup>29</sup>. Keratinocytes and fibroblasts secrete laminin and type IV collagen to restore the injured basal lamina. The keratinocytes then change shape in the newly formed *Stratum basale* and become columnar and start to divide to establish a new epidermis<sup>28</sup>.

### *Remodelling Phase*

Tissue remodelling or scar maturation starts when collagen production is equal to degradation. The balance is regulated by matrix metalloproteinases (MMPs), such as collagenases, gelatinases, and stromelysins, which are responsible for the degradation of ECM components<sup>28</sup>. During maturation, type III collagen is gradually replaced by the stronger type I, and disordered collagen fibres are organized and cross-linked to increase the tensile strength of the wound. The ultimate strength of wounded skin reaches about 80% of that of normal skin. The remodelling phase may last for a year or more depending of the nature of the wound<sup>31</sup>.

## Immune Systems

### An Overview

Immunity is the ability of the host to resist infection or disease. The vertebrate immune system is divided into one innate and one adaptive part. Innate immunity is the first and oldest defence of the body and refers to everything that is already present. This includes physical barriers and epithelial cells, neutrophils and macrophages as well as their effectors, the complement system, proteins with direct antimicrobial effects, and AMPs. This immune system is fast and unspecific in action. On the other hand, adaptive immunity or acquired immunity is slow; a primary immune response takes up to seven days and a secondary response takes about three days<sup>32</sup>. The adaptive immune response evolved ~450 million years ago, in the period between the jawless and jawed fishes<sup>33</sup>. It is specific and inducible in action and can discriminate between self and non-self. The adaptive immunity is able to remember pathogens that the organism has come across earlier. It comprises lymphocytes with the B-cell derived repertoire of antigen specific antibodies, and activated B- and T-cells as immunological memory. During evolution, natural selection has made adaptive immunity a common feature of all vertebrates.

In the early 20<sup>th</sup> century, there was much controversy between the two fields of immunology, ‘cellular’ and ‘humoral’. The conflict was to some extent resolved and the importance of both fields was emphasized in 1908, when the Nobel Prize in Physiology and Medicine was shared between Metchnikoff ‘cellularist’, and Ehrlich, ‘humoralist’, for the cooperative interactions between innate and adaptive immunity<sup>34</sup>. This cooperation is well illustrated in the ‘classical’ pathway of the complement system where antigen-antibody complexes trigger activation of the system, ultimately leading to microbial killing either by the membrane attack complex (MAC) or by phagocytosis of C3b-opsonized bacteria. Another example from the ‘classical’ pathway is our own finding that factor C3a and its inactive derivative C3a<sub>desArg</sub> exert strong direct antimicrobial activity<sup>35</sup>. Dendritic cells

constitute yet another important link between the two immune systems. They contribute to innate immunity by expressing TLRs and by their phagocytic activity, and to adaptive immunity by presenting antigens to naïve T-cells via the major histocompatibility complex (MHC) class II<sup>36</sup>.

## Innate Immunity

Innate immunity is a rapid and universal form of immunity; the majority of organisms survive with only this type of defence system. The innate immune system is ancient in origin and found in all studied multicellular organisms. Mechanisms of innate immunity are dynamic during evolution, because microbes impose selective pressures on the host resulting in survival of the fittest.

The starting point for research in innate immunity must be attributed to Ilya Metchnikoff, who in 1884 announced his theory of phagocytosis. He had witnessed the engulfment of particulate dyes and fungal spores by ‘wandering cells’ in invertebrates<sup>37</sup>.

Innate immunity comprises both constitutive and inducible mechanisms. Included in constitutive defences are physical barriers, like the skin epithelium and different types of mucosal epithelia, antimicrobial proteins, and AMPs — the subject of this thesis. The inducible mechanisms in innate immunity differ from those in adaptive immunity. They are rather non-specific and use conserved molecular patterns to recognize pathogens, such as bacterial lipopolysaccharides (LPS) and lipoteichoic acids (LTA)<sup>32</sup>. The induced innate defence is rapid, requiring only minutes to hours. It includes the activation of phagocytes, such as PMNs and macrophages, other leukocytes, such as mast cells, the lectin pathway of complement, and signalling pathways that result in transcription of different genes involved in immune response, like cytokines and other inflammatory mediators<sup>32,38</sup>. Some AMPs are also inducible in nature like hBD-2, which is induced from epithelial cells by interleukin-1 (IL-1)<sup>39</sup>.

### *Recognition of Microbes*


The inducible innate defence recognizes microbes by non-clonally distributed receptors that sense certain molecules exclusively found on the surface of microbes and not on self-tissues. These molecules are called pathogen associated molecular patterns (PAMPs) and the receptors are collectively named pattern recognition receptors (PRRs)<sup>36</sup>. One important type of PRRs is the TLRs<sup>40</sup>. The *TLR* family of genes are evolutionary very old and are conserved in both invertebrates and vertebrates<sup>41,42</sup>. The receptors were called Toll-like because of the homology to the first receptor found in this class, the receptor Toll described in *Drosophila*. The *Toll* pathway was found to regulate the synthesis of an antifungal peptide, drosomycin<sup>43,44</sup>. The vertebrate TLRs are found on the surface of epithelial cells, macrophages, dendritic cells, and PMNs.

### *The Complement System*

The complement system is an evolutionary old and significant part of innate immunity. It is activated either directly or indirectly by microbes. The system includes about 35 different proteins and their activation proceeds in a cascade fashion eventually resulting in bacterial opsonisation by C3b. This is followed by either phagocytosis or the assembly of a pore-forming MAC on the bacterial surface, both leading to lysis and destruction of bacteria. The system can be activated via three pathways that differ only in their formation of the C3 convertases in the initiation of the cascade<sup>45</sup>.

They are called the classical, alternative and lectin pathway (figure 3). The classical pathway is triggered by antigen-antibody complexes and activation of C1qrs leads to activation of the classical C3 convertase, C4bC2a. In the absence of antigen-antibody complexes, an alternative spontaneous conversion of C3 to C3b is triggered by different surfaces. On the host cell surface, inhibitory proteins and sialic acid immediately stop the complement cascade. On foreign surfaces, like bacteria,

inhibitory substances are not present and C3b binds Factor B, forming an alternative C3 convertase (C3bBb) and more C3b are converted from C3. An alternative pathway positive feedback loop thereby amplifies the initially small amounts of C3b. The lectin pathway is started when mannan binding lectin (MBL) binds to bacterial surfaces with mannan containing polysaccharides. The surface binding of MBL generates an association between two MBL-associated serine proteases, (MASP-1 and MASP-2, which are homologous to C1r and C1s in the classical pathway) and the active MBL/MASP-1/MASP-2 complex activates C4 and C2<sup>45</sup> to generate the classical C3 convertase.



**Figure 3.** Overview of the complement cascade. The three initiation pathways are underlined and the release of the anaphylatoxins is shown in grey. The starting material of each pathway is presented in a rectangle. MBL = mannan binding lectin, MASP = mannan binding lectin associated serine protease and MAC = membrane attack complex.


Peptides with anaphylatoxic activity are released during the complement cascade, C3a, C4a and C5a. These peptides are proinflammatory agents. They bind to receptors on basophils and mast cells and thereby mediate degranulation and histamine release. They promote enhanced vascular permeability and contraction of smooth muscle cells. The C5a peptides also mediate chemotaxis during inflammation with attraction of leukocytes to the site of infection. In addition, C5a triggers leukocyte activation, and generation of cytotoxic oxygen radicals.

The complement factor C3a is a cationic peptide (pI 11.3) of 77 amino acids with a molecular weight of 9.083 kDa (figure 4). The secondary structure of C3a contains four  $\alpha$ -helical regions and six cysteine residues that are responsible for the formation of three intrachain disulphide bridges. The folding of the compact C3a molecule is mainly dependent on these disulphide bonds. The plasma concentration of C3 is 5 - 11  $\mu$ M and during inflammation additional amounts of C3 are generated by monocytes and keratinocytes<sup>46,47</sup>. C3a may therefore be generated in micromolar concentrations at the site of complement activation. In sepsis patients levels of up to 0.5  $\mu$ M of C3a has been measured in blood<sup>48</sup> and in patients suffering from acute media otitis concentrations of approximately 0.7  $\mu$ M C3a are found in ear secretions<sup>49</sup>. C3a may be present in significant amounts in blood, but its anaphylatoxin activity is under strict regulation by the serum protease carboxypeptidase N, which cleaves off the C-terminal arginine residue generating the inactive peptide C3a<sub>desArg</sub><sup>50</sup>. The primary structures of C3a from different species are distinct, but some common characteristics are believed to be essential for maintaining function. The three disulphide bridges that stabilize the structure are for instance important. The binding site of C3a to its receptor is located in the far C-terminal LGLAR peptide, which are also highly conserved between species. This explains the site of action of the regulating protease. It is important to note that many of the amino acid replacements in C3a that occur between species are conservative, meaning that they maintain characteristics like side-chain size, polarity and shape, which minimize the 3D consequences of the change<sup>50,51</sup>.

---

An additional important activity of C3a is presented in this thesis. The peptide is proven to be a potent antimicrobial agent<sup>35,51,52</sup>. Its antimicrobial activity is highly conserved during evolution from invertebrates to humans and it seems that this activity is more connected to the 3D structure of the molecule than to the primary structure, that shows significant sequence variations<sup>51</sup>. Interestingly, evolutionary pressures on functionality and structure must have been imposed on C3a to preserve critical features important for antimicrobial activity side by side with the development of the other immunologically important activities of this peptide.

SVQLTEKRM<sup>D10</sup> KVGKYPKELR<sup>20</sup> KCCEDGMREN<sup>30</sup> PMRFSCQRRT<sup>40</sup>  
 RFISLGEACK<sup>50</sup> KVFLDCCNYI<sup>60</sup> TELRRQHARA<sup>70</sup> SHLGLAR<sup>77</sup>



**Figure 4.** Amino acid sequence and molecular models of C3a. Underlined is the CNY21 peptide, the smallest C3a peptide known to possess nearly full anaphylatoxic activity<sup>53</sup>. Left:  $\alpha$ -helical regions in the molecule are indicated. Right: Three intrachain disulphide bridges (C22-C49, C23-C56, and C36-C57) and numbered amino acid residues are shown from N-terminal S1 to C-terminal R77.

## Antimicrobial Peptides

AMPs are ancient and essential components of the fast acting innate immune system in probably all classes of life<sup>32</sup>. During evolution these peptides have obtained high efficiency in spite of highly mutable target microbes with a fast generation time. This suggests an important co-evolution between hosts and

pathogens. About 1400 AMPs are now defined in a variety of life forms (<http://aps.unmc.edu/AP/main.php>)<sup>54</sup>, including plants<sup>55</sup>, insects<sup>56</sup>, amphibians<sup>57</sup>, fishes<sup>58</sup>, birds<sup>59</sup>, and mammals<sup>60</sup>. AMPs are also found in prokaryotes as a defence against competing local microbes<sup>1,61</sup>.

AMPs comprise a diverse spectrum of activity against various targets such as bacteria, fungi<sup>62</sup>, protozoa<sup>63</sup>, enveloped viruses<sup>64,65</sup>, and even tumour cells<sup>66,67</sup>. Some AMPs display broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, and fungi<sup>68</sup>, whereas other peptides are specialists, like cecropin P1<sup>69</sup> showing activity only against Gram-negative bacteria. AMPs are primarily constitutively expressed, but at special sites in the body the expression may be induced in response to certain stimuli like cytokines, bacteria, and PAMPs. The killing of microorganisms and the destruction of bacterial plasma membranes by human AMPs occurs at micromolar concentrations, but fortunately normal human host cells are relatively resistant at those concentrations<sup>70</sup>. Synergistic effects are found between different AMPs, but also between AMPs and larger antimicrobial proteins like lysozyme<sup>71</sup>. Synergy means that the activity is increased more than additively by the combination of factors.


### *Host Defence Peptides*

It has been increasingly evident that many AMPs possess complementary abilities, besides their direct antimicrobial effects, in modulating the innate and inflammatory responses<sup>72-74</sup> (figure 5). AMPs are found to influence inflammation, affect chemotaxis and accumulation of leukocytes at inflammatory sites<sup>75-77</sup>, enhance phagocytosis, neutralize the effects of LPS, stimulate release of prostaglandin, promote angiogenesis<sup>78,79</sup> and induce wound healing<sup>32</sup>. Other biological activities of AMPs include promotion of apoptosis<sup>80-82</sup>, antiangiogenesis, inhibition of proteases, as well as stimulation of cell growth. Many AMPs show rather weak or no direct antimicrobial activity in physiological high salt conditions (see below), but in the same environment are both potent and selective immunomodulatory agents. LL-37

---




has been demonstrated to trigger multiple signalling pathways, including the classical Mitogen-activated protein (MAP) kinase pathway, by using a specific intracellular receptor resulting in induction of different chemokines<sup>83</sup>. Cathelicidins (LL-37, BMAP-27 and indolicidin) are also found to suppress the effects of LPS, leading to reduced production of proinflammatory cytokines like TNF- $\alpha$ <sup>84-86</sup>. By neutralizing LPS, cathelicidins may protect the host from endotoxaemia and toxic shock. LL-37 and BMAP-27 both reduce substantially various LPS-induced chemokines<sup>86</sup>, indicating a role for cathelicidins in maintaining homeostasis during endotoxin challenge by balancing the pro- and anti-inflammatory responses. Because of the many immunomodulatory effects of antimicrobial peptides these molecules are currently frequently referred to as host defence peptides (HDP)<sup>87</sup>.



**Figure 5.** Multifunctionality of AMPs or host defence peptides (HDPs). Interestingly, AMPs/HDPs maintain homeostasis by simultaneously promote pro- and anti-inflammatory immune responses. Small circles represent bacteria or bacterial products. Schematic view modified from Brown and Hancock 2006<sup>88</sup>

## Structure

Despite diverse origins of AMPs, they have several biophysical parameters in common. Small size, cationicity, amphipathicity and hydrophobicity are probably important factors for the efficacy of AMPs. AMPs are relatively short polypeptides (< 10 kDa), generally composed of between 12 and 60 amino acid residues. Their net charge is positive (+2 to +9) with about 50% hydrophobic amino acids and an excess of basic residues (arginine, lysine and/or histidine). The secondary structure is often of amphipathic nature<sup>32,89</sup>, consisting of both a significant non-polar and a polar part. Amphipathicity of a peptide means that there is a spatial separation between hydrophobic and hydrophilic amino acid side chains in the molecule. Amphipathicity can be determined by calculating the hydrophobic moment, which is the vector sum of the hydrophobicities of each amino acid residue perpendicular to the axis of the helix. The mean hydrophobic moment per residue is used to compare amphipathicity between peptides of different length<sup>90</sup>. A more descriptive way to present amphipathicity of an  $\alpha$ -helical peptide is to show a helical wheel projection<sup>91</sup>, where polar and non-polar amino acids are distributed into discrete sectors of the wheel (figure 6). Many AMPs are salt-sensitive and therefore inactive in the presence of physiological salt. This sensitivity is proposed to be due to instability of the  $\alpha$ -helical structure in addition to strong electrostatic interactions in high salt conditions<sup>92</sup>. Capping of the N- and C-terminal ends of salt-sensitive AMPs is a way to stabilize the helical structure, and the result indeed results in salt-resistant antimicrobial peptides<sup>92</sup>. However, studies have shown that increasing helicity and helix-stability of antimicrobial peptides may not only increase the antimicrobial activity but also the toxicity of these peptides against eukaryotic cells<sup>93</sup>.



**Figure 6.** Helical wheel projection of three antimicrobial peptides. The cathelicidin LL-37, the heparin-binding consensus sequence ARK24 and the C3a-derived peptide CNY21. Red indicates hydrophobic (non-polar) residues and blue hydrophilic (polar) residues, dark red indicates less hydrophobicity and black indicates intermediate residues.

### *Classes of Antimicrobial Peptides*

AMPs are a very diverse group of molecules and there are different ways to categorize these peptides. Here I have chosen a subgrouping according to the primary and secondary structure and with regard to the origin of the peptides. Most of the AMPs fit into one out of four major subgroups<sup>94</sup>; linear cationic  $\alpha$ -helical peptides; cationic peptides with  $\beta$ -strands stabilized by disulphide bonds; cationic peptides enriched for certain amino acid residues; cationic peptide fragments of larger proteins. An additional very small subgroup consists of anionic peptides.

The subgroup of **linear cationic  $\alpha$ -helical peptides** is the most studied group of AMPs. These linear peptides do not contain disulphide bridges and cysteine residues and typically consist of less than 40 amino acid residues<sup>95</sup>. Many of these AMPs are unstructured, extended or linear in aqueous solutions, but are able to adopt an  $\alpha$ -helical conformation in hydrophobic environments, like in the closeness of membrane lipid bilayer structures<sup>89,95</sup>. The extent of  $\alpha$ -helicity is well correlated with the antimicrobial activity of these peptides. Increased  $\alpha$ -helical content gives

increased antimicrobial effects<sup>96</sup>. AMPs with this secondary structure include for example cecropins<sup>11,97,98</sup>, magainins<sup>12</sup>, dermaseptins<sup>99</sup>, buforin II<sup>96</sup> and LL-37<sup>100,101</sup>.

The AMPs in the subgroup of **cationic peptides with  $\beta$ -strands stabilized by disulphide bonds** often have several antiparallel  $\beta$ -strands and the structures are stabilized by up to six disulphide bridges<sup>102</sup>. This is a highly diverse group of peptides and conventional multiple sequence alignments (MSA), in the N- to C-terminal orientation, found no consensus motifs with respect to the primary structure. However, by using stereospecific MSA, a general pattern was discovered among all antimicrobial peptides that are stabilized by disulphide bridges<sup>103</sup>. This characteristic cysteine motif, called the  $\gamma$ -core motif, includes 8 to 16 amino acid residues and a conserved GXC or CXG motif within the sequence<sup>103</sup>. Other characteristics of the  $\gamma$ -core motif are a net positive charge (+0.5 to +7) with basic amino acids polarized along the axis of the motif; amphipathicity; and a stabilizing function of at least one disulphide bridge<sup>103</sup>. Peptides in this subgroup include for instance, protegrin from pigs, tachyplesins from horseshoe crabs<sup>104</sup> and the different defensins,  $\alpha$ -defensins<sup>105</sup>,  $\beta$ -defensins<sup>106</sup>, rhesus  $\theta$ -defensin<sup>107</sup> and insect defensins<sup>108</sup>.

AMPs containing one or more amino acids that are overrepresented belong to the subgroup **cationic peptides enriched for certain amino acid residues**. The predominant residues are often proline/arginine, histidine, or tryptophan. These AMPs are variable in structure and not well characterized. Examples are PR-39 from pigs, with an overrepresentation of proline and arginine; the human histatins, with a large amount of histidine residues<sup>109</sup>; the bovine indolicidin, with the highest tryptophan content of any known protein residues.

The fourth subgroup is based on the origin of the peptide and the members are **cationic peptide fragments of larger proteins**. All novel antimicrobial peptides presented in this thesis are representatives of this subgroup. Examples of peptides are lactoferricins from lactoferrin<sup>110,111</sup>, casocidin-I from bovine casein<sup>112</sup>,

---

hemocidins from apohemoproteins like hemoglobin, myoglobin and cytochrome c<sup>113,114</sup>, C3a from C3<sup>35</sup>, degradation products of high molecular weight kininogen (HMWK)<sup>115,116</sup> and antimicrobial and heparin-binding domains from many different endogenous proteins<sup>117</sup>. These peptide fragments show strong antimicrobial effects and share biophysical parameters with conventional AMPs, as described above, but their actual importance in innate immunity needs to be further investigated. Interestingly, the main bactericidal action of human seminal plasma is due to peptides generated by proteolytical degradation of semenogelin I and II<sup>118</sup>. Semenogelins, and the peptides derived thereof, are rich in histidin residues, and could therefore also fit in the subgroup of peptides enriched for certain amino acids. Semenogelin peptides, in common with most other histidin-rich polypeptides, exhibit zinc-dependent antimicrobial effects<sup>118</sup>.

A small additional subgroup of AMPs is identified as **anionic peptides**. Three of these peptides are present in human surfactant extracts, bronchoalveolar lavage fluid, and in airway epithelial cells. They are very small in size, rich in glutamic and aspartic acids, and require zinc as a cofactor for antimicrobial activity<sup>94</sup>. These peptides are totally different from the well-characterized cationic AMPs and they are thought to be a part of the innate pulmonary defence system. Collectively, they are called surfactant-associated anionic peptides (SAAP)<sup>119</sup>. Other anionic AMPs are maximin H5 isolated from the toad *Bombina maxima*<sup>120</sup> and dermcidin from human sweat glands<sup>121</sup>. The modes of action of these anionic AMPs have not been completely revealed.

Many AMPs are unstructured in aqueous solution and are folded into an amphipathic formation when they come in contact with a membrane. This is true for AMPs forming  $\alpha$ -helices, but also for peptides enriched for certain amino acid residues, which often fold into more extended structures. Disulphide stabilized  $\beta$ -sheet or  $\beta$ -hairpin peptides are regularly prefolded in their secondary and tertiary structure in solution. Independent of the 3D arrangement, and when the folding of

the peptides takes place, the final structure contains some hydrophobic parts and some charged hydrophilic parts that enable peptide interactions with bacterial plasma membranes<sup>122</sup>.

## Main Families

Mammals have two main families of AMPs; the cathelicidins and the defensins<sup>16</sup>. Cathelicidins are made as inactive precursors and the antimicrobial peptide becomes active when it is proteolytically cleaved off from the C-terminal end of the protein. Mammalian defensins are instead stored in their mature active forms and their structure is based on a  $\beta$ -sheet core stabilized by three disulphide bridges.

### *Cathelicidins*

Cathelicidins are synthesized as prepropeptides. They have a general structure of a signal peptide in the far N-terminal end, a very conserved proregion in the middle, and a highly variable C-terminal part, containing the antimicrobial peptide. Cathelicidins are processed in two steps. First, the signal peptide is cleaved off and second, the mature AMP is activated by release. These peptides are stored in cells in the propeptide form. The conserved proregion is called the cathelin-like region because of the high sequence identity with the pig *cath*epsin *L* inhibitor, cathelin. The genes encoding cathelicidins are evolutionary conserved and generally include four exons. The first encodes the signal peptide, the second and third encode the cathelin-like region, and the fourth exon encodes the processing site and the antimicrobial domain.<sup>123</sup> Cathelicidins are mainly produced in the bone marrow and stored in granules of neutrophils<sup>124</sup>, but human LL-37 is also found to be expressed in monocytes, macrophages<sup>125</sup>, B-cells and T-cells<sup>75</sup>. However, some cathelicidins are also identified in epithelial cells, like keratinocytes in inflamed skin<sup>100</sup> and in the epithelia of the human lung<sup>100,126</sup>, indicating a local role for these molecules. Examples of mammalian cathelicidins are proline-arginine-rich PR-39 and protegrins from pigs, CRAMP from mice, bovine BMAP-27, BMAP-28, Bac5 and

Bac7<sup>123</sup>. In addition, cathelicidins are also found in a few other species like fish<sup>127</sup> and chicken<sup>128</sup>.

The only human cathelicidin protein is hCAP-18 (human cationic antimicrobial protein-18, 18 kDa), with its active AMP, LL-37 (figure 7) – a peptide of 37 amino acids (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLPRTES). *CAMP* (cathelin antimicrobial peptide) is the gene encoding hCAP-18 and it is located on chromosome 3p21.3<sup>129</sup>. hCAP-18/LL-37 is found at high concentrations (40  $\mu$ M or  $\sim$ 630  $\mu$ g/ $10^9$  cells)<sup>130</sup> in its unprocessed form in the peroxidase-negative granules of human neutrophils<sup>129</sup>. The propeptide is processed upon degranulation by the serine protease proteinase 3 from azurophilic granules of neutrophils, either in the phagolysosome or in the extracellular environment, and the active LL-37 peptide is cleaved off and released<sup>131</sup>. hCAP-18/LL-37 is also present in high concentrations in seminal plasma<sup>132</sup>. Interestingly, when seminal plasma enters the vagina after sexual intercourse, the progastricsin becomes activated by the acidic milieu and the proteolytic enzyme gasticsin is able to process hCAP-18 and release the active AMP<sup>133</sup>. This is probably a way to lower the risk of infection following sexual intercourse.


Besides their antimicrobial effects, cathelicidins have a number of additional functions as HDPs. Two receptors are for example found to be involved in cell signalling mediated by LL-37 in leukocytes. LL-37 interacts with the G protein-coupled receptor known as formyl peptide receptor-like 1 (FPRL1), a signalling pathway leading to chemoattraction of neutrophils, monocytes, T-cells<sup>76</sup>, and eosinophils<sup>134</sup>, and the purinergic P2X<sub>7</sub> receptor, known to mediate LL-37 induced processing and release of interleukin-1 beta<sup>135</sup>. LL-37 has also been demonstrated to activate and release histamine from mast cells<sup>76</sup> and to inhibit HIV-1 replication. The HIV-1 inhibitory effect was also shown to be independent of FPRL1 signalling<sup>136</sup>.

### *Defensins*

Like cathelicidins, the defensins are synthesized as prepropeptides, which are then processed to various extents to release the active peptides. Three subfamilies of defensins are known in mammals;  $\alpha$ -defensins,  $\beta$ -defensins and  $\theta$ -defensins. All three subfamilies have features in common including, rather short peptides (18 - 45 amino acids, 2 - 6 kDa) with a net positive charge (+1 to +11), and three intramolecular disulphide bridges with tertiary structures dominated by turn-linked  $\beta$ -strands. The spacing between the cysteines and location of the disulphide bonds differ between  $\alpha$ -defensins and  $\beta$ -defensins<sup>137</sup> (figure 7). It was assumed that the disulphide bond and the tertiary structure were essential for the antimicrobial activity of the defensin peptides, but now data indicates that protection from proteolysis is the main function of the intramolecular bridges. It is however shown that substitution of the cysteines completely abolishes the chemotactic activity of human  $\beta$ -defensin 3 (hBD-3), but the antimicrobial activity remains unaffected in the absence of disulphide bridges<sup>138</sup>. Despite the differing secondary structure of  $\alpha$ -defensins and  $\beta$ -defensins, their tertiary (3D) structure is very similar (figure 7)<sup>17</sup>. The genes encoding  $\alpha$ -defensins, *defa*, and the most studied  $\beta$ -defensins, *def $\beta$* , are found in the same region of chromosome 8 (8p23) in a 450 kb segment, and it is suggested that the  $\alpha$ -defensin gene family has evolved from a common ancestral  $\beta$ -defensin gene<sup>139</sup>.

Six different  $\alpha$ -defensins are identified in humans, human neutrophil peptides 1 - 4 (HNP 1 - 4) and human defensins 5, 6 (HD-5, 6). Four of them (HNP 1-4) are expressed systemically and stored in azurophilic granules of neutrophils<sup>140</sup>. Interestingly, half of the protein content of these granules is actually comprised of HNP-1, -2 and -3, whereas HNP-4 occurs in lower concentrations<sup>141</sup>. Recently, expression of HNP1-3 has also been found in human monocytes<sup>142</sup> and natural killer cells<sup>143</sup>. HD-5 and HD-6 are primarily expressed in the human intestinal Paneth cells<sup>144</sup>, where the processing of the propeptide (proHD-5) is mediated by Paneth cell trypsin<sup>145</sup>. However, HD-5 has also been found in vagina, cervix, and Fallopian tubes in the human female reproductive tract<sup>146</sup>.





**Figure 7.** Representatives of the main families of mammalian AMPs, cathelicidins (A) and defensins (B). (A) Schematic drawing of the human cathelicidin prepropeptide hCAP-18 with the C-terminal AMP LL-37. (B) The processed peptides of defensins with disulphide bridges.  $\alpha$ -defensin (left),  $\beta$ -defensin (middle) and  $\theta$ -defensin (right).

In 1993 a set of defensin-like peptides from bovine PMNs called  $\beta$ -defensins were discovered<sup>137</sup>. The increasing family of vertebrate  $\beta$ -defensins has at the moment ~60 members, including 43 from mammals, 6 from birds and 11 ( $\beta$ -defensins-like peptides) from marsupials and reptiles<sup>147</sup>. Although about 30 human  $\beta$ -defensin genes have been identified with bioinformatics<sup>148</sup>, only four peptides (hBD-1,

hBD-2, hBD-3, and hBD-4) have so far been isolated. In contrast to  $\alpha$ -defensins  $\beta$ -defensins are generally expressed locally in epithelial cells. hBD-1 was the first human  $\beta$ -defensin to be found. Its gene is constitutively expressed by several epithelia directly exposed to the surrounding microbial flora (e.g. lung, salivary gland and kidney)<sup>149</sup>. hBD-1 is present in plasma and some truncated forms are found in urine, but the peptide was first purified from hemofiltrate from kidney dialysis patients. hBD-2 and hBD-3 were later isolated from the scales of psoriatic skin<sup>17</sup>. The expression of both hBD-2 and 3 are induced by inflammatory stimuli (such as TNF- $\alpha$ )<sup>150</sup>. By using bioinformatics including the Basic Local Alignment Search Tool (BLAST), novel genes in the 8p23 cluster were found (hBD-4-6)<sup>151,152</sup>. The fourth  $\beta$ -defensin to be isolated was hBD-4, with the highest expression level found in the testis and in the gastric antrum<sup>153</sup>. In 2002, also by the use of bioinformatics, three new  $\beta$ -defensin gene clusters (at 6p12, 20q11.1 and 20p13), containing 28 novel human  $\beta$ -defensin genes, were discovered<sup>148</sup>. However, isolation of these  $\beta$ -defensins has not yet been reported.

$\theta$ -defensins, the third subfamily of defensins, are cyclic peptides that arise from two precursor peptides containing nine amino acid residues each. They are only found as pseudogenes in humans and in New World monkeys, but are fully expressed in several species of Old World monkeys (like Rhesus macaque and Pigtail macaque) and in the ape orangutans. The human  $\theta$ -defensin mRNA is not translated due to a premature stop codon in the transcripts<sup>154</sup>. In Rhesus macaque  $\theta$ -defensin is only detected in neutrophils and monocytes.<sup>107</sup> The  $\theta$ -defensins antiviral properties are much more powerful than their antibacterial and antifungal effects. Interestingly, the  $\theta$ -defensins retrocyclin 1 and especially retrocyclin-2 show striking activity against human immunodeficiency virus (HIV-1), herpes simplex virus-1 (HSV-1), and herpes simplex virus-2 (HSV-2).

## Mode of Action

AMPs can be divided into membrane or non-membrane active<sup>94</sup>. Most linear cationic  $\alpha$ -helical AMPs are suggested to form pores in and disrupt the anionic bacterial plasma membrane<sup>155</sup>, but alternative mechanisms, involving interaction with intracellular targets exists<sup>156,157</sup>.

### *Membrane Active AMPs*

Amphipathicity in the molecule, with amino acid residues segregated into distinct hydrophobic or cationic regions, is a crucial secondary structure in most AMPs. Regardless of the mechanism of the final killing of the bacteria, AMPs have to interact with the bacterial plasma membrane, either to cross the membrane or to rupture it. The precise nature of this interaction between amphipathic  $\alpha$ -helical AMPs and biological membranes is not completely understood, although extensively studied and much debated.

Nevertheless, it has been shown that peptide-lipid interactions, rather than receptor-mediated recognition, are important in the function of many membrane active AMPs<sup>158</sup>. Three specific steps in the membrane action are identified: attraction, attachment, and peptide insertion. Attraction is mainly due to electrostatic bonding. Cationic AMPs are thought to be attracted to the anionic outer envelope (LPS or phospholipids) of Gram-negative bacteria and to the teichoic acids of Gram-positive bacteria. The peptides have to pass through the layers of LPS in Gram-negative bacteria and polysaccharides, teichoic acids, and/or lipoteichoic acids in Gram-positive bacteria to be able to attach and interact with the outer membrane or the cytoplasmic membrane, respectively. How this is mediated for different AMPs is not fully elucidated. However, when the  $\alpha$ -helical peptides reach the membrane bilayer they embed themselves, due to hydrophobic interactions, into the region of the lipid head groups. This embedded state of peptides is called surface state (S state). AMPs in this state are orientated parallel to the membrane and are

functionally inactive, but the lipid bilayer is stretched and membrane thinning is mediated. The thinning effect is specific to the AMP and is directly proportional to the concentration of peptide<sup>159</sup>. When the peptide concentration is increased and the correct peptide-to-lipid molar ratio is reached for the specific combination of AMP and membrane, a transition from S state to the pore-forming peptide insertion state (I state) will occur. Peptides in the I state are orientated perpendicularly in the membrane and are able to form transmembrane pores<sup>159</sup>, leading to destruction of the transmembrane electrochemical potential and pH gradient, an altered osmotic regulation, inhibited respiration, and eventually complete collapse of the membrane and cell death. Four different (three of them are presented in figure 8) models have been proposed to describe membrane permeabilization by amphipathic  $\alpha$ -helical peptides: the “aggregate” model, the barrel-stave model, the toroid-pore model, and the carpet model<sup>94,160</sup>


**The aggregate model** proposes that AMPs cross the membrane as peptide-lipid complexes and the peptides in these complexes form irregular aggregates within the membrane without adopting any particular orientation<sup>161</sup>.

In **the barrel-stave model** the formation of transmembrane pores is made by bundles of peptides. AMPs assemble as multimers on the surface of the membrane (S state) and in the I state the peptides are inserted into the hydrophobic core of the membrane lipid bilayer. The hydrophilic side of the  $\alpha$ -helical peptides form the interior of the transmembrane pore and the hydrophobic side align the lipid core. Additional peptide monomers are then recruited and attached to the bundle leading to an increase in the size of the pore<sup>94</sup>. The fungal peptide alamethicin is the best studied AMP that uses the barrel-stave type of pore<sup>160</sup>.

**The toroid-pore model** describes the formation of pores or channels in the membrane by monomers of peptides. The polar or hydrophilic side of the peptides associate with the polar heads of the lipids. When the  $\alpha$ -helical peptides insert into the

membrane they induce the lipids to tilt and connect the two layers of the bilayer membrane, thereby forming a bend continuously through the pore. Both the lipid head groups and the inserted AMPs make a hydrophilic lining all through the pore. This model differs from the barrel-stave model in the continuous association between the peptides and the lipid head groups, and also in the I state of the peptides. Magainins, protegrins, and LL-37 induce this type of pore in bacterial membranes<sup>94</sup>.

According to **the carpet model** the AMPs bind as monomers with their hydrophobic sides against the surface of the lipid bilayer and their hydrophilic sides facing the solvent. The peptides will cover the membrane as a carpet and permeabilization will occur only after a threshold peptide-to-lipid molar ratio has been reached<sup>162</sup>. In order to form a carpet of cationic peptides, the presence of negatively charged lipids (acidic phospholipids) is important because this minimizes the repulsive force between all positively charged AMPs<sup>160</sup>. In this model, AMPs are neither inserted into the hydrophobic core of the bilayer nor assembled in bundles. At high concentration of peptides, when the transition into I state has occurred, the AMPs disrupt the membrane in a detergent-like manner, which eventually leads to the formation of micelles<sup>94,163</sup>. As an intermediate stage in this model, toroid-pores or wormholes are formed and low molecular weight molecules are able to leak out of the microbe prior to total membrane collapse<sup>162</sup>. The carpet model describes the action of for example dermaseptin S<sup>164</sup>, cecropin<sup>165</sup>, and melittin<sup>166</sup>.



**Figure 8.** Mode of action of membrane active AMPs. Barrel-stave model, toroid-pore model, and carpet model are shown. See text for details. Schematic illustration modified from Brogden 2005<sup>94</sup>.

#### *Non-Membrane Active AMPs*

Instead of membrane rupture some AMPs use intracellular targets that activate different pathways and lead to bacterial killing. Receptor-mediated activity has been reported for some *Drosophila* AMPs<sup>70</sup>. Non-membrane active AMPs, which do not activate receptors on the surface of microbes, have to cross the plasma membrane and they have developed a variety of mechanisms to do this. These AMPs are either bactericidal or bacteriostatic in the cytoplasm. They can modify membrane septum formation, bind DNA (buforin II and tachyplesin), inhibit cell-wall synthesis (the lantibiotic mersacidin), or inhibit enzymatic activity (histatins). Dermaseptin, pleurocidin, PR-39, indolicidin, and HNP-1 are AMPs that inhibit DNA, RNA, and protein synthesis. PR-39 and indolicidin can also induce a very elongated morphology of the microbe, indicating that cell division in these cells is prevented<sup>94</sup>. Some cationic amphipathic peptides are able to bypass the receptor step and directly activate G-proteins in mast cells, leading to degranulation and histamine release.

Venom peptides, neuropeptides, and hormones are also included in this family of peptides<sup>167</sup>.

### *Membrane Specificity for AMPs*

Most  $\alpha$ -helical peptides are rather harmless to normal host cells. The toxicity to microbes is due to the high amount of anionic lipids in their membranes, a considerable electrical potential gradient over the bilayer, and a lack of supportive lipids, like the steroid-alcohol cholesterol, in the membrane. The majority of AMPs that have a high net positive charge and contain basic amino acids spread all over the hydrophilic side of the  $\alpha$ -helix, are non-haemolytic and non-toxic to mammalian cells. On the other hand, AMPs that have a low net positive charge and a very high helix content are more harmful to both bacterial and mammalian cells. The negatively charged bacterial plasma membranes have a high content of acidic phospholipids, whereas the membranes of normal mammalian cells are neutral and predominantly composed of zwitterionic phosphatidylcholine and sphingomyelin phospholipids. Highly positively charged peptides preferentially act against the negatively charged bacterial membrane and have low or no affinity to zwitterionic mammalian membranes<sup>162</sup>. However, it should be mentioned that certain AMPs are potentially toxic to mammalian cells including, the bee AMP melittin<sup>168</sup>, the frog AMP temporin L<sup>169</sup>, the scorpion charybdotoxin, and the wasp venom mastoparan<sup>122</sup>.

### *Determination of Antimicrobial Activity*

Generally, the antimicrobial activity of an antimicrobial agent, including antibiotics and AMPs, is presented as a MIC-value. Minimal Inhibitory Concentration (MIC) is defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a specific microorganism after overnight incubation. The MIC-value is usually determined by using either agar or broth dilution assay<sup>170</sup>. MICs are presented in mg/l or M (mol/litre).

### *Synergy among AMPs*

The biological activities of antibiotics or antimicrobial peptides are generally examined in isolation. However, in nature different AMPs and larger antimicrobial proteins affect microbes simultaneously, and they will inevitably interact with each other despite differences in their spectra of activity. Studies suggest that this interaction between AMPs is important for the final antimicrobial activity and may lower the amount of a single peptide required to enhance antimicrobial activity. The term synergy means that the resulting antimicrobial activity of peptides interacting with each other is more than the sum of their individual antimicrobial activities. The fractional inhibitory concentration (FIC) is an interaction coefficient indicating whether the combined inhibitory effect of drugs is synergistic, additive, or antagonistic<sup>171</sup>. To calculate FIC for the combination of AMP A and B, the following formula is used;  $FIC_{AB} = FIC_A + FIC_B$ .  $FIC_A = MIC_{AB} / MIC_A$  and  $FIC_B = MIC_{AB} / MIC_B$ , where  $MIC_{AB}$  is the MIC of the combination A + B,  $MIC_A$  is the MIC of AMP A alone and  $MIC_B$  is the MIC of AMP B alone. Interpretations of the FIC index varies in different studies, but generally FIC values  $\leq 0.5$  show synergy, FIC = 1 shows additive effects, and FIC  $\geq 4$  show antagonistic effects.

Peptides may also show synergy in their antimicrobial mechanism. The magainin family of peptides from the African clawed toad (*Xenopus laevis*) magainin 2, and PGLa are examples of such peptides. Both form pores in the cytoplasmic membrane leading to membrane disruption. The magainin 2 peptide forms pores at a rather slow rate, but the pores formed are relatively long-lived. In contrast, PGLa is able to form pores very rapidly, but they are rather unstable and thereby short-lived. When magainin 2 and PGLa work in synergy, they form complexes that have the advantage of each individual peptide: both fast pore formation and increased pore stability<sup>172</sup>. Other examples are the two-component bacteriocins, where each component shows very little or no antimicrobial effect, but acting in combination their effects increase dramatically<sup>173</sup>.



## Bacterial Resistance Strategies

Various microbes are not equally susceptible to AMP activity, and it seems like the ability to circumvent AMP killing is a selective quality of a number of common and significant human pathogens. Some pathogens like *Staphylococcus aureus* and *Salmonella* spp. are generally very resistant to AMPs compared with other similar organisms<sup>174</sup>. As an interesting connection, *S. aureus* is also known to be the most common cause of human wound infections and abscesses in deep tissues and *Salmonella* spp. are the major cause of chronic systemic infections in otherwise healthy individuals. On the other hand, microbes that are more susceptible to AMPs, for instance *Escherichia coli*, may cause a local infection at the mucosal surface but are generally not able to infect deep tissues unless the patient is in some way immunosuppressed. Recently, a broad diversity of bacterial strategies to resist AMP killing have been identified<sup>175</sup>. Some bacterial species modify the normal anionic cell surface in various ways, and thereby alter the cell surface charge. The teichoic acids in the cell wall of Gram-positive bacteria and the lipopolysaccharides in the outer membrane of Gram-negative bacteria are modified in these AMP resistant strains. The modifications include for instance introduction of  $\text{NH}_3^+$  in different ways. The substitutions make the surface less negatively charged and it will repulse, rather than attract cationic AMPs<sup>175</sup>.

Another resistance strategy is binding of and/or blocking AMPs which leads to neutralization and inactivation. These AMP-inhibitory proteins can be either surface-associated or secreted<sup>175</sup>. An example is the *S. aureus* staphylokinase, which induces secretion of  $\alpha$ -defensins from human PMN, forms a complex with them and causes near complete inhibition of their bactericidal effect<sup>176</sup>. Microbes may also induce release of host molecules that bind and inactivate AMPs. Some pathogens secrete proteases that are able to degrade negatively charged proteoglycans attached to the surface of host epithelial cells. For instance, proteases from *S. pyogenes*, *E. faecalis*, and *P. aeruginosa* degrade the proteoglycan decorin, and thereby release the GAG dermatan sulphate (DS). Released DS are then able to bind and inactivate

$\alpha$ -defensins<sup>24</sup>. In paper I in this thesis, we demonstrate that the GAGs DS and chondroitin sulphate (CS-E) is able to bind and inactivate the AMP LL-37<sup>25</sup>. In the same paper, we show that proteases from common pathogenic bacteria (*P. aeruginosa*, *E. faecalis*, *P. mirabilis* and *S. pyogenes*) degrade LL-37<sup>25</sup>. Proteolytic degradation is yet another strategy for microbes to resist the action of host antimicrobial peptides. Other examples are the metalloprotease aureolysin from *S. aureus* that also cleaves and inactivates LL-37<sup>177</sup> and proteases from *E. coli* and *S. aureus* that inactivate bovine Lactoferricin B<sup>178</sup>.

Active energy-dependent efflux systems represent significant mechanisms for resistance against conventional antibiotics, but may also contribute to the resistance of some microbes against cationic AMPs of the innate immune system. For example, *Neisseria gonorrhoeae* express an efflux system that ejects hydrophobic antibacterial agents and thereby gives increased resistance to antibiotics like penicillin and erythromycin. It has been demonstrated that gonococcal resistance to the AMPs protegrin-1 and LL-37 is altered by over expression of the same genes that control this efflux system<sup>175</sup>.

Even though it seems like there is a selective pressure for resistance against AMPs, many bacterial species remain sensitive. Why? Probably, there must be a balance between the bacterial gain in being resistant and the bacterial metabolic cost for a mutation to take place and to retain it. Some mutations may just be metabolically too expensive for the bacteria.

## Antimicrobial Proteins

Recently, an increasing number of cationic proteins considerably larger than the classical AMPs have been shown to be directly antimicrobial. There is an informal limit of approximately 50 amino acids in length separating the smaller peptides from the larger proteins. Alexander Fleming was the first one to observe and described the activity of an antimicrobial polypeptide, lysozyme from human respiratory

---

secretions<sup>179</sup>. Other proteins with antimicrobial activity are found in airway secretions, including lactoferrin and Secretory Leucoprotease Inhibitor (SLPI). In this environment, lysozyme and lactoferrin are the most abundant, with concentrations of between 0.1-1 mg/ml<sup>180</sup>.

Many different proteins with antimicrobial properties are now known. Some examples are; the two iron binding proteins, transferrin from plasma<sup>71</sup> and lactoferrin isolated from respiratory secretions, breast milk, tears, gastrointestinal fluid, cervicovaginal mucus, seminal fluid, and secondary granules of PMNs<sup>181</sup>, the gastric protein pepsinogen C<sup>71</sup>, cathepsin G - a major protease released by activated neutrophils<sup>182</sup>, the liver derived plasma protein histidine-rich glycoprotein (HRG)<sup>183</sup>, the bactericidal/permeability increasing protein (BPI)<sup>184</sup>, and the heparin binding protein (HBP)<sup>183,185</sup>, both isolated from azurophilic granules of human PMN.

Many proteins with a previously well-defined and established function have recently been described to also possess potent antimicrobial effects. Some interesting findings include the neuropeptides substance P and neuropeptide Y<sup>186-188</sup>, peptide hormones<sup>187,189</sup>, the complement anaphylatoxins C3a<sup>35,52</sup>, and C4a<sup>51</sup>. Activation of the intrinsic pathway of coagulation via the contact system is found to release proteins and peptides with potent antimicrobial effects, such as bradykinin (BK)<sup>186,187</sup> and domain 3 (D3)<sup>115</sup>. In addition, in paper IV we describe antimicrobial activities of domain 5 (D5)<sup>116</sup> from HMWK. Many chemokines<sup>190,191</sup> and several different growth factors<sup>192</sup> are very similar to AMPs in size, charge, amphipathicity, and heparin-binding abilities and are also shown to be antimicrobial<sup>192</sup>.

The antimicrobial effect is not the only and perhaps not the main activity of these proteins, but their complexity of functions is poorly understood. Possibly, the antimicrobial effect is the original function of a certain protein before more specific and specialized functions were developed during evolution, as in the case of the complement factor C3a<sup>51</sup>. Nevertheless, the antimicrobial properties may still be of

great importance in a particular environment under special circumstances and in concert with the more specific actions of the protein. Interestingly, the antimicrobial domain is usually traced to a cationic, amphipathic, and heparin-binding sequence in the larger protein and in many cases peptides released by acid hydrolysis of the larger protein have potent antimicrobial effects, like for instance lactoferricins and kaliciocins from lactoferrin<sup>89</sup> and buforin I from histone H2A<sup>193</sup>.

### Antimicrobial Defences of the Skin

Human skin epidermis cells are able to produce many different innate immunity molecules<sup>194,195</sup>. Healthy keratinocytes and sweat glands together constitutively produce lysozyme, SLPI, RNase 7<sup>196</sup>, dermcidin<sup>197</sup>, cathepsin D<sup>198</sup>, and LL-37<sup>199</sup>. It has also been demonstrated that LL-37 from skin and sweat is further processed into smaller peptides with increased antimicrobial activity<sup>200,201</sup>, probably enabling a shift in the activity of LL-37 from being largely immunomodulatory toward being pure antimicrobial. A local production of the AMPs hBD-2, hBD-3, and LL-37 is induced during inflammation in skin keratinocytes. This induction may come from the action of pro-inflammatory cytokines<sup>39,202</sup> as well as growth factors<sup>203</sup>. In response to microbial stimuli, Langerhans cells in the skin secrete inflammatory mediators like IL-1, which then are able to induce the expression of different AMPs in keratinocytes<sup>39</sup>. Damaging the skin is actually enough to induce AMPs at relevant concentrations. This is mediated by heparin-binding epidermal growth factors (EGF) that are released from keratinocytes. These growth factors bind and activate epidermal growth factor receptors (EGFR), leading to expression of different AMP genes and production of for example hBD-3<sup>204</sup>. Keratinocytes also produce and secrete an 11 kDa protein called psoriasin in response to the Gram-negative bacteria *E. coli*. Psoriasin is found to be the main mediator of *E. coli* killing in human skin<sup>205</sup>. It has also been revealed that ultraviolet light (UVB) from the sun indirectly induces expression of the *CAMP* and *defβ2* genes in human keratinocytes. Vitamin D is formed in the skin by UV-light and it has been demonstrated *in vivo* that vitamin D

induces expression of the *CAMP* gene and upregulation of the production of hCAP-18 as a result<sup>206,207</sup>. Other cell types in the skin that produce LL-37 are neutrophils<sup>208</sup> and mast cells<sup>209</sup>.

## Antimicrobial Peptides in Clinical Medicine

The importance of AMPs in innate immunity is well established and different clinical studies have blamed defective AMP activity for impaired bacterial clearance. Many AMPs are known to be salt-dependent, and fail to work properly in high salt conditions. The airway surface fluid from patients with cystic fibrosis (CF) has elevated levels of Na<sup>+</sup> and Cl<sup>-</sup>, caused by mutations in a gene encoding a phosphorylation-regulated Cl<sup>-</sup>-channel found in normal airway epithelia<sup>210</sup>. This increase in ionic strength is a key factor contributing to deficient antimicrobial activity in this fluid<sup>211</sup>. HBD-1-3 are salt-dependent AMPs and are thereby inactivated in these patients<sup>212</sup>. Another interesting finding, is that hBD-2 and 3 are proteolytically degraded by the cysteine proteases cathepsins B, L, and S, which are found in high amounts in CF airway fluid<sup>213</sup>. A recent study highlights that LL-37 is also inactivated in CF patients, either as a result of LL-37 interaction with DNA, filamentous actin, and cell debris, or interaction between LL-37 and the Gram-negative bacterial endotoxin LPS, which all are abundant in CF sputum. It is also interesting to note that LL-37 activity could be enhanced by addition of LBP, which competes with LL-37 for binding to LPS<sup>214</sup>.

### *Deficiency or Abundance*

Different medical conditions are connected with deficiency or overproduction of AMPs, leading to certain physical consequences for the patients. Patients suffering from specific granule deficiency (SGD) lack  $\alpha$ -defensins and patients with Chediak-Higashi syndrome (CHS) have a severe deficiency of both cathepsin G and elastase in their PMNs. These patients frequently suffer from serious bacterial infections and the lack of important AMPs in these diseases is thought to contribute

to defective microbial killing<sup>215</sup>. Another example is the disorder morbus Kostmann, where patients have a congenital deficiency of neutrophils. Treatment with recombinant granulocyte-colony stimulating factor restores the amount of neutrophils, but despite normal levels, these neutrophils are found to be deficient in the cathelicidin LL-37 and have only reduced amounts of the  $\alpha$ -defensins HNP1-3. There was a total lack of LL-37 in plasma and saliva, which could explain why all people with morbus Kostmann syndrome also suffer from frequent oral bacterial infections and severe periodontal disease<sup>216</sup>. LL-37 and hBD-2 are also downregulated in keratinocytes in atopic dermatitis skin lesion, whereas LL-37 and hBD-2 are instead overexpressed in psoriatic lesions<sup>217,218</sup>. Psoriatic skin is also known to express a blend of other AMPs, including psoriasin<sup>219</sup>. This may explain why about 30% of the patients suffering from atopic dermatitis have microbial infections of the skin, compared with only 7% of the psoriasisics<sup>220</sup>. Recently, it has also been proposed that LL-37 in fact is a central trigger of the pathogenesis and autoimmunity of psoriasis. LL-37 is found to bind to self-DNA and this complex is then able to translocate into endosomes of plasmacytoid dendritic cells and signal through TLR-9, leading to induce an interferon- $\alpha$  response. TLR-9 is an intracellular receptor that is usually only activated by viral or microbial DNA. The location of TLR-9 inside cells is a safeguard against autoimmunity and the recognition of self-DNA in normal healthy skin. By binding self-DNA, LL-37 breaks this self tolerance and yields a similar response as viral or microbial DNA, with an induction of interferons which then initiate innate and adaptive immunity<sup>221</sup>.

#### *AMPs as Future Therapeutics*

Antimicrobial peptides are promising agents in our search for new and potent therapeutics for topical or systemic administration. They are interesting candidates against pathogenic microbes, but also as immunomodulatory agents. Their broad spectra activity with a rapid action, the low potential for pathogen resistance on repeated exposure, and the low toxicity for eukaryotic cells are attractive features.

Many AMPs are immunomodulatory (figure 5), but have only limited immunogenicity<sup>32</sup>. Their small size makes them easy to synthesize even though the substantial expense of peptide synthesis must still be overcome.

There are studies where synthetic host defence peptides (HDPs) have been constructed without any direct antimicrobial activities, and these peptides were still shown to efficiently protect against bacterial infection<sup>83</sup>. These results indicate that direct antimicrobial activity is not a requirement for protection against infection. However, knowledge of all the *in vivo* interactions and all the immunomodulatory effects of AMPs must be further elucidated in order to assess safety before being administered systemically. A database, [www.innatedb.com](http://www.innatedb.com), is now available presenting all known interactions and signalling pathways involved in the mammalian innate immune response<sup>222</sup>. As more research is carried out, this database of knowledge will grow bigger and will probably be an important tool in understanding the complexity of actions of AMPs/HDPs. With increased knowledge and understanding, there is a great potential for a therapeutic use of these immunomodulatory and anti-infective AMPs/HDPs. These cationic peptides will probably circumvent issues of antimicrobial resistance because they do not eliminate microbes directly.

AMPs of evolutionary distant origins are found to be functionally very similar, and the knowledge and understanding of the design of lower invertebrate peptides will be of great help in the development of new antibiotics, host defence and / or immunomodulatory agents in humans. A good example is plectasin from the black cup fungus *Pseudoplectania nigrella*. Plectasin is the first defensin isolated from the fungi kingdom and it shows homology with plant and insect defensins. This AMP has a great therapeutic potential and tests on mice have shown very promising results<sup>223</sup>, with strong activity against many multiresistant strains primarily among Gram-positive bacteria.

Drugs derived from AMPs are already in clinical trials. Pexiganan (MacroChem Corporation, NY), a drug derived from the magainin family<sup>12</sup> of AMPs are used as topical treatment for diabetic foot infections, and omiganan pentahydrochloride (MBI-226)<sup>224</sup> (Cutanea Life Sciences, PA), an analog of the bovine cathelicidin indolicidin, will be used clinically for the prevention of infections in catheters. Promising clinical Phase III trials with omiganan are also underway for the treatment of the chronic dermatologic disorder, Rosacea.

Another area of research with potential therapeutic value is the development of therapeutics that will stimulate expression of certain AMPs and thereby augment endogenous antimicrobial activity.





## **PRESENT INVESTIGATION**

### **Aims of the Thesis**

The general aim was to study antimicrobial peptides present in wounds during inflammation and healing.

We specifically wanted to:

- Investigate the stability of LL-37 in the presence of chronic or acute wound fluids.
- Study the effects of common bacterial proteases against LL-37.
- Investigate whether LL-37 is bound to various GAGs, and if so study the effect on LL-37 of this binding.
- Test our hypothesis that motifs associated with heparin-binding may confer antimicrobial properties to any given peptide.
- Identify novel endogenous antimicrobial peptides from heparin-binding motifs that may be generated by proteolysis during inflammation.
- Investigate if the cationic complement factor, C3a is a heparin-binding peptide. In that case may this anaphylatoxin also possess potent antimicrobial activity?
- Elucidate whether the heparin-binding and cell-binding D5 of HMWK is antimicrobial. Identify shorter antimicrobial peptides within the D5 sequence.

## Results and Discussion

### Paper I

Here we show that proteases of common human pathogens degrade and inactivate the AMP LL-37. The metalloproteinase, elastase (LasB or pseudolysin) from *Pseudomonas aeruginosa*, was found to hydrolyze LL-37. The generated fragments were analyzed by LC-MS TOF and MS-MS TOF. *P. aeruginosa* elastase cleaves LL-37 in the central part, where the antimicrobial activity has been ascribed<sup>225</sup>, and it preferentially cleaved at sites with hydrophobic residues (Ile, Leu, Phe) in the P1' position. This finding corresponds well with the P1' specificities reported for the thermolysin-like family of proteases, to which *P. aeruginosa* elastase belongs<sup>226</sup>. Fragments of LL-37 generated within 30 min of incubation with *P. aeruginosa* elastase exerted only residual antimicrobial activity. Furthermore, the inhibition of LL-37 mediated killing was also tested. A non-elastase producing strain of *P. aeruginosa* was incubated together with LL-37 with and without added *P. aeruginosa* elastase, the suspensions were plated and after overnight incubation the colony forming units were counted. A clear survival advantage was noticed for bacteria in the presence of increasing amounts of *P. aeruginosa* elastase. Growth media from *Enterococcus faecalis* and *Proteus mirabilis* contains *E. faecalis* gelatinase and the *P. mirabilis* metalloproteinase ZapA, respectively. These growth mediums and also the purified *Streptococcus pyogenes* cysteinyl protease (streptococcal pyrogenic exotoxin B (SpeB)) were also able to degrade LL-37, as determined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Inhibitors of the proteases were able to block this degradation of LL-37.

We showed that human chronic wound fluids degrade LL-37, whereas acute wound fluids do not. It is known that chronic wounds, in contrast to acute wounds, are largely colonized with bacteria. Our data indicate that the bacterial proteases present in chronic ulcers may be responsible for the inactivation and degradation of LL-37. To test this further, the following *ex vivo* experiments were performed. An elastase

producing *P. aeruginosa* isolate and a non-elastase producing *P. aeruginosa* isolate were separately added into sterile wound fluid, grown to stationary phase and the mixtures were incubated with LL-37 for increasing periods of time. The *P. aeruginosa* elastase producing isolate induced degradation of LL-37 leading to enhanced bacterial survival. The resistance of the LL-37-region of the proprotein (hCAP18) against *P. aeruginosa* elastase was also tested. HCAP18 was incubated with conditioned media from the elastase-positive and elastase-negative isolates of *P. aeruginosa*. The results were visualized by SDS-PAGE and western blotting, using polyclonal antibodies against LL-37. Interestingly, degradation was shown after only 10 min of incubation at 37°C in the samples containing the protease. Previously, it was reported that  $\alpha$ -defensins bind to GAGs and this binding inhibited the antimicrobial action of the peptide<sup>24</sup>. In this study we wanted to see if the same was true for LL-37. Indeed LL-37 was bound to and inactivated by DS (CS-B) (figure 2a) and the closely related CS-E. The binding not only blocked the antimicrobial activity of LL-37, it also protected the peptide from degradation by *P. aeruginosa* elastase.

In summary, the proteolytic degradation of LL-37 by bacterial proteases presented in this paper may be an important bacterial virulence mechanism. It may provide a way for microbes to circumvent the host immune system, both the direct antimicrobial activity of LL-37 but also all the other immunomodulatory actions of this peptide. The role of GAGs as inhibitors of LL-37 activity, but also their role as protectors of LL-37 against bacterial proteolytic degradation, remains to be elucidated.

## Paper II

As we demonstrated in paper I, LL-37 is bound to DS and CS-E, GAGs very similar in structure to heparin. The biophysical parameters common for many otherwise very different AMPs are cationicity, amphipathicity and  $\alpha$ -helicity. These characteristics are also common among heparin-binding peptides. In this study we

---

wanted to see more generally, if peptides with structural motifs associated with heparin affinity also hold antimicrobial activity.

In paper II, we demonstrate that synthetic peptides derived from heparin-binding motifs of endogenous proteins, all involved in or present in certain ways during inflammation, are indeed antimicrobial. Heparin-binding sequences from laminin, fibronectin, von Willebrand factor, protein C inhibitor, vitronectin, and complement factor C3 were synthesized. Both viable count analysis (bactericidal activity) and radial diffusion assay (inhibition of growth) were used to analyse antimicrobial activity. The microorganisms tested were *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Proteus mirabilis* and also the fungi *Candida albicans*. Heparin-binding activity was confirmed or determined by using a slot binding technique with radiolabelled heparin. In 1989, Cardin and Weintraub<sup>227</sup> proposed consensus sequences for heparin-binding peptides, XBBBXXBX or XBBXBX (where X represents hydrophobic or uncharged amino acids, and B represents basic amino acids). Antimicrobial activity was also tested for synthetic peptides of different lengths, with amino acids organised in the Cardin and Weintraub patterns [AKKARA]<sub>1-4</sub> and [ARKKAAKA]<sub>1-3</sub>. The larger peptides (AKK24 and ARK24) were shown to exert potent activities, similar to the effects of LL-37. *P. aeruginosa* was incubated with some of the peptides at LD<sub>50</sub> and the bacteria were then fixed, stained, and analysed by electron microscopy. Morphological differences compared to the control were demonstrated with local perturbations and breaks along the bacterial plasma membrane. In this study, we reveal that heparin-binding motifs of endogenous proteins exhibit antimicrobial activities. In addition, the Cardin and Weintraub motifs and also the laminin-derived peptides RLR22 and the shorter variant PGR11, showed that too short peptides were not as active as larger variants, probably due to their inability to form a stable  $\alpha$ -helix.

During the inflammatory phase in normal wound healing, there is a massive degradation of the damaged tissue before the regeneration starts. ECM proteins and

different blood and plasma proteins are highly degraded, and our findings indicate a novel antimicrobial role for this cell debris. In general, our finding that many heparin-binding peptides also possess antimicrobial properties may ease the search for novel AMPs in complex biological mixtures.

### Paper III

During complement activation C3a may be generated in blood in micromolar concentrations, but it is strictly regulated and controlled by inactivation by carboxypeptidase N. The carboxypeptidase cleaves off the C-terminal arginine residue generating the C3a<sub>desArg</sub> peptide<sup>50</sup>. The structural features of factor C3a resemble those of many AMPs. C3a is cationic (pI 11.3), contain four  $\alpha$ -helices, and as described in paper II, possesses heparin-binding sequences<sup>117</sup>. This prompted us to investigate the antimicrobial effects of the complete C3a. In paper III, we describe the antimicrobial activity of the anaphylatoxin C3a and also of the inactive C3a<sub>desArg</sub> peptide, indicating an important additional function for these complement peptides. Even after inactivation of the anaphylatoxin C3a, the resulting C3a<sub>desArg</sub> peptide may contribute to innate immunity by its direct antimicrobial activity. By using radial diffusion assay (RDA), the minimal effective concentrations (MEC) for C3a were determined at 0.70  $\mu$ M and 0.75  $\mu$ M against *P. aeruginosa* and *E. coli* respectively. This could be compared with a MEC of 1.0  $\mu$ M LL-37 for *E. coli*.

Earlier studies have described four helical regions of C3a<sup>50</sup>. We ordered synthetic peptides spanning the four helices to investigate whether these epitopes were carrying the antimicrobial activity. A peptide known to exert full anaphylatoxic activity (CNY21), the inactive peptide (CNY20), and finally the smallest peptide with any activity (LGL5)<sup>50</sup>, were also synthesized. RDA and viable count analysis revealed that the complete C3a molecule (77 aa), but also the synthetic peptides are active against *E. coli*, *P. aeruginosa*, and *E. faecalis*. Interestingly, C3a showed potent antimicrobial activity also in physiological salt conditions. Heparin-binding capacities of the peptides were analysed by slot-binding-assay with radiolabelled

---

heparin. Fluorescence and electron microscopy demonstrated that the C3a and the there of derived peptides bind to and induce breaks in the bacterial plasma membrane. C3a was also shown to induce membrane leakage of liposomes. Furthermore, one of the C3a-derived peptides (CNY21), was found to suppress infection by *S. pyogenes* in mice. By using western blot analysis with an antibody against one of the synthetic C3a peptides (LGE27), we found that acute wound fluid incubated together with lysed neutrophils generated C3a-like peptides. We also showed that shorter degradation products of C3a are generated by neutrophil elastase, where at least one of them is stable. This peptide was sequenced and synthesized and found to exert similar antimicrobial effects as the CNY21 peptide. Paper III presents an important and interesting link between two key branches of innate immunity, the complement system and antimicrobial peptides.

#### Paper IV

In paper IV we show that recombinant D5 (rD5) of HMWK is antimicrobial. HMWK is a 120 kDa glycoprotein found in plasma (~80 µg/ml) and in  $\alpha$ -granules of platelets. It is present during normal wound healing and inflammation.

By analysing synthetic overlapping peptides within the D5 sequence, we wanted to reveal the location of the bactericidal activity. The antimicrobial part was found in the His-Gly-Lys-rich subdomain (Gly<sup>475</sup>-Lys<sup>502</sup>) of D5, the same region which also shows strong Zn<sup>2+</sup>-independent binding of heparin.<sup>228</sup> All three peptides (GGH20, HKH20, and GKH17) from this region exerted potent activity against *E. coli* in RDA. The most potent peptide against *P. aeruginosa* and *E. faecalis* in RDA, HKH20 (His<sup>479</sup>-His<sup>498</sup>), was also shown to efficiently kill *E. coli*, *P. aeruginosa*, and *E. faecalis* in viable count analysis. Using RDA, the MEC of HKH20 against *P. aeruginosa* was estimated to be 0.4 µM. The interaction between HKH20 and bacteria was studied by fluorescence microscopy and electron microscopy. By using fluorescent dye labelled HKH20, microscopy revealed that HKH20 was attached to the *P. aeruginosa* surface, and this binding was blocked by heparin. The binding of heparin to rD5

and HKH20 was confirmed in the slot-binding-assay with radiolabelled heparin. Electron microscopy demonstrated that HKH20 caused local perturbations and breaks along the *P. aeruginosa* plasma membrane, but also that intracellular material was found extracellularly. Importantly, HKH20 was found to be antimicrobial in physiological salt conditions and in the presence of plasma. The results of assays for hemolysis, LDH-release, and MITT-assay showed no lytic effects of HKH20 against eukaryotic cells. Interestingly, in contrast to LL-37 (paper I) and  $\alpha$ -defensin<sup>24</sup>, HKH20 was found to be very stable and not degraded by *P. aeruginosa* elastase. Since HMWK is not antimicrobial by itself, we also wanted to know if D5-peptides might be generated after proteolytic cleavage of HMWK. Proteolytic degradation of HMWK was carried out *in vitro* with human neutrophil elastase, lysed PMN, as well as the bacterial *P. aeruginosa* elastase. This indeed generated an antimicrobial blend, as demonstrated by RDA against *E. coli*. Analysis with SDS-PAGE revealed that HMWK was indeed degraded into multiple fragments and both *P. aeruginosa* elastase and neutrophil extracts yielded smaller peptides. Western blot analysis demonstrated that some of the generated peptides were derived from the His-Gly-Lys-rich subdomain of D5 and thereby recognized by an anti-HKH20 antibody. One of the peptides generated after digestion by *P. aeruginosa* elastase was analysed by Edman degradation and MALDI-TOF. The peptide generated was LDD40 (Leu<sup>461</sup>-Gly<sup>500</sup>). A synthetic peptide LDD40 was found to be antimicrobial against *E. coli* and *E. faecalis*. Although proteolytic degradations were only studied *in vitro*, this result indicates a release of antimicrobial D5 peptides during inflammation and proteolysis. During activation of coagulation via the intrinsic pathway (contact activation), plasma kallikrein releases the inflammatory mediator bradykinin and D3-derived AMPs from HMWK<sup>115</sup>. Proteolytic cleavage and the release of bradykinin causes a conformational change in the resulting two chain HMWK (called HMWKa), exposing the heparin-binding and cell-binding D5<sup>229</sup>. In summary, paper IV reveals a previously unknown antimicrobial activity of D5 in HMWK.



## Conclusions

- Wound fluid from chronic skin ulcers degrades LL-37, whereas wound fluid from acute wounds does not.
- Common human pathogens, *P. aeruginosa*, *E. faecalis*, *P. mirabilis*, and *S. pyogenes*, produce proteases that inactivate and degrade LL-37. This indicates an important bacterial virulence mechanism.
- GAGs, like dermatan sulphate and heparin, bind LL-37 and thereby inhibit the antimicrobial activity. However, the binding can also protect the peptide from proteolytic degradation by bacterial proteases.
- There is an association between antibacterial activity of a peptide and its ability to bind heparin. Consensus sequences for heparin-binding peptides show potent antimicrobial activity against *E. faecalis*, *P. aeruginosa*, *E. coli*, and *P. mirabilis*, but also against the fungi *C. albicans*.
- Various matrix, plasma, and blood proteins that are known to be degraded during inflammation carry antimicrobial motifs.
- Novel antimicrobial properties have been established for both the anaphylatoxin C3a and its inactive variant C3a<sub>desArg</sub>, peptides generated during complement activation.
- Domain 5 of HMWK is antimicrobial and antimicrobial sequences within D5 have been characterized.
- A synthesized D5 peptide HKH20, shows broad antimicrobial activity with a strong effect also in the presence of physiological salt and plasma. Furthermore, HKH20 is not degraded by *P. aeruginosa* elastase.

## Concluding Remarks

A healthy, balanced system has very low levels of antimicrobial peptides (AMPs). After injury and during inflammation production of AMPs is increased in several ways. AMPs are generated in response to infection by signalling through receptors like TLRs and EGFR<sup>230</sup>, via recruited neutrophils, and via complement activation (paper III). Interestingly, the anaphylatoxic and antimicrobial C3a peptide may also be generated via activation of the intrinsic pathway of the coagulation system (factor Xa and XIa)<sup>231</sup>. It has also been shown that the trauma alone in a non-infected wound may induce expression of AMPs via transactivation of the EGFR<sup>204</sup>. During normal wound healing, the inflammation phase is characterized by massive degradation of the damaged ECM, generating fragments of different matrix, blood, and plasma proteins. Many of the degraded proteins contain heparin-binding and antimicrobial sequences that may be released (paper II, IV), indicating a novel role for innate immunity in this mixture of inflammatory peptides. After the generation of protein fragments, the degradation process continues until the area is cleared and the healing process enters the proliferative phase with reepithelialisation. If there is a prolonged period of high inflammation, the balance in the system could be lost. Instead of being an important part of healing, the inflammation is now devastating for the host. All the protein fragments containing potential antimicrobial peptides will be totally degraded and their potential activities lost. Bacteria are still colonizing the wound and bacterial proteases are able to inhibit and degrade AMPs like  $\alpha$ -defensin<sup>24</sup> and LL-37 (paper I). Proteoglycans from the epidermis and dermis are also broken down and GAGs, such as dermatan sulphate and heparan sulphate, are released. These GAGs may possibly bind and inhibit the action of  $\alpha$ -defensin<sup>24</sup> and LL-37 (paper I). Instead of the normal healing process, bacteria are now in control of the area. Although very simplified, this is probably the scenario in many chronic infective processes such as chronic skin ulcers.



## POPULÄRVETENSKAPLIG SAMMANFATTNING

Ett bra immunförsvar är viktigt för att förhindra sjukdom vid angrepp av bakterier och virus. Kroppens försvar kan delas upp i ett snabbt medfött och ett långsammare förvärvat immunsystem. Det förvärvade är baserat på antikroppar som sedan fungerar som minnesmolekyler vid framtida infektioner. Det kan ta veckor innan det förvärvade immunförsvaret har sin fulla verkan. Det medfödda immunförsvaret aktiveras däremot direkt som svar på en infektion. Till det medfödda immunförsvaret hör dels fysiska barriärer så som huden och slemhinnor eller ogästvänliga miljöer som magsäckens saltsyra, dels olika sorter av vita blodkroppar. Ett exempel på vita blodkroppar är neutrofiler som kan äta upp (fagocytera) inkräktande bakterier eller skicka ut inflammatoriska ämnen (cytokiner) som på olika sätt leder till att inkräktaren oskadliggörs.

En annan viktig del av det medfödda och snabba immunförsvaret är antimikrobiella peptider, vilket är ämnet för denna avhandling. En peptid är ett kort protein och antimikrobiella peptider är oftast inte längre än 60 aminosyror (de byggstenar som bygger upp alla protein). De är direkt bakterie-, svamp- eller virusdödande. Vidare är de positivt laddade med en amfipatisk struktur, d.v.s. de har en vattenskyende och en vattenlöslig sida. Deras struktur samt den positiva laddningen gör att de har förmåga att binda till, tränga igenom och ta i sönder de negativt laddade bakteriemembranen. Andra antimikrobiella peptider verkar inne i bakterien, där de stör livsviktiga processer som t.ex. förmågan att producera proteiner. Antimikrobiella peptider är evolutionärt sett väldigt gamla och återfinns inom alla klasser av liv; djur, växter, svampar, men även bland bakterier, såsom ett försvar mot konkurrerande bakterier. Antimikrobiella peptider blev först kända för deras direkta bakteriedödande effekt, men numera har man sett att deras verkan är mycket mer komplex än så och att de spelar en mängd olika roller i vårt immunförsvar (de är s.k. immunomodulatoriska) för att skydda oss mot eller bli av med en befintlig infektion. Idag känner man till ca 1400 antimikrobiella peptider och med mer forskning

upptäcks fler hela tiden. Bland annat har ett flertal peptider med andra, sedan tidigare kända, funktioner nyligen visat sig även vara antimikrobiella, som exempel kan nämnas vissa tillväxtfaktorer och komplement faktorn C3a (delarbete III).

Antimikrobiella peptider är bra kandidater för att utveckla nya mediciner som kan användas istället för eller som komplement till konventionell antibiotika, vilket är viktigt i dessa tider då antibiotikaresistensen hos våra vanliga sjukdomsbakterier ökar lavinartat. Bra egenskaper är att antimikrobiella peptider har effekt mot många olika typer av bakterier samt vissa virus och verkar inte utveckla resistens på samma sätt som konventionell antibiotika. Intressant är t.ex. en antimikrobiell peptid (retrocyclin 2) från rhesus apa som visat sig ha en mycket påfallande effekt mot HIV-virus, och lovande mediciner håller på att utvecklas. Det pågår några kliniska prövningar med läkemedelskandidater som är baserade på antimikrobiella peptider. Det handlar då främst om krämer som appliceras lokalt vid hud och sårvård. Däremot måste den immunomodulatoriska effekten av peptiderna klarläggas helt och hållet innan man vågar använda antimikrobiella peptider i terapier systemiskt i kroppen.

I **delarbete I** har vi sett att några av våra vanligaste bakterier släpper ut olika proteiner som bryter ner den antimikrobiella peptiden LL-37. LL-37 är en peptid som finns i hög koncentration i de vita blodkroppar som kallas neutrofiler. Det är bl.a. dessa som rekryteras i stor utsträckning vid inflammation vid t.ex. sårläggning. Bakterierna har alltså på detta sätt utvecklat en strategi för att undkomma verkan av LL-37. Vi har även visat att de bakterier som producerar ett sådant protein överlever behandling med LL-37 i mycket högre grad än de som inte bildar detta protein. Kroniska sår (t.ex. liggsår och diabetessår) är till skillnad från akuta (t.ex. vanliga skärsår och rivsår) fullpackade med bakterier. Normal sårläggning börjar med en inflammationsfas, då bl.a. neutrofiler strömmar till och den skadade vävnaden bryts ner för att vid nästa fas i sårläggningen kunna ersättas med frisk vävnad. I akuta sår hålls bakterierna i schack av kroppens snabba immunförsvar, medan

läkningsprocessen i kroniska sår istället har fastnat i en inflammatorisk fas och bakterierna har i många fall tagit överhanden. Det är sedan tidigare känt att olika bakterieproteiner även kan bryta ner strukturer i huden och därigenom frisätta negativt laddade sockerkedjor s.k. polysackarider (t.ex. dermatansulfat). I detta delarbete har vi visat att hudens eget dermatansulfat, frisatt av bakterieproteiner eller långvarig inflammation, binder till och förhindrar verkan av LL-37. Intressant är att bindningen skyddar LL-37 från nerbrytning av bakterieproteiner.

I **delarbete II** har vi tittat vidare på det faktum att negativt laddade polysackarider binder till positivt laddade antimikrobiella peptider. Förutom dermatansulfat i huden så finns det en del snarlika polysackarider i människan, den mest kända är heparin som också är välkänd för sin blodförtunnande effekt. Eftersom LL-37 binder heparin så kan man kalla den för en heparinbindande peptid. Många heparinbindande peptider och/eller heparinbindande delar av ett större protein är kända sedan tidigare. Vår frågeställning i detta delarbete var av generell karaktär. Är en heparinbindande peptids form och struktur densamma eller snarlik den form och struktur som karakteriserar en antimikrobiell peptid? Är i så fall de flesta heparinbindande peptider antimikrobiella?

1989 presenterades generella utseenden av peptider, vilka ger dessa optimal förmåga att binda till heparin. Peptider med detta ”principutseende” testades i försök med bakterier och peptiderna var verkligen starkt bakteriedödande. Det framkom också att peptiderna inte bör vara alltför korta, förmodligen beroende på att de då inte kan in ta den mest fördelaktiga 3D-strukturen för att kunna interagera med bakteriemembranen. Syntetiska peptider från olika kända heparinbindande protein som på olika sätt finns närvarande vid inflammation och sårhäkning testades också. Även dessa peptider visade sig i försök vara starkt bakteriedödande. Inflammationen vid sårhäkning kännetecknas av kraftig nedbrytning av vävnad och de proteiner som vi undersökt blir alla sönderdelade till småbitar. Det är därför troligt att många heparinbindande peptider med antimikrobiell funktion finns närvarande vid

---

sårsläkningen och har där tillsammans med andra försvarsmekanismer den viktiga uppgiften att hålla såret fritt från bakterier. Upptäckten att många heparinbindande peptider också är antimikrobiella är viktigt, då det gör det möjligt att lättare hitta nya antimikrobiella peptider genom att använda sig av deras förmåga att binda till heparin.

I **delarbete III** har vi visat en tidigare okänd antimikrobiell verkan av peptiden C3a i komplementsystemet. Komplementsystemet är en del av vårt medfödda försvar som aktiveras vid infektion. Namnet kommer av att det är ett komplement till immunförsvaret och dess uppgift är att oskadliggöra inkräktande bakterier. C3a är en 77 aminosyror lång peptid som frisätts vid aktivering av komplementsystemet. Den är känd för att dra igång kraftig inflammation och om pådraget blir för stort kan resultatet likna en allergisk chockreaktion. Den inflammatoriska verkan av C3a regleras i kroppen genom att peptiden inaktiveras då en aminosyra i ena änden klipps av, peptiden kallas då C3a<sub>desArg</sub>. I detta delarbete har vi visat att även C3a är heparinbindande peptid som mycket effektivt dödar bakterier. En intressant och viktig upptäckt är att också C3a<sub>desArg</sub> är kraftigt antibakteriell, eftersom det är denna variant av C3a som finns tillgänglig under en längre period vid inflammation och sårsläkning. På omslaget av avhandlingen finns bilder tagna med hjälp av ett elektronmikroskop föreställande pseudomonasbakterier före (uppe till vänster) och efter behandling med C3a (uppe till höger) och C3a<sub>desArg</sub> (nere till höger). Verkan av kortare syntetiska peptider från C3a molekylen har också testats och även dessa har stark antibakteriell effekt. En av dessa peptider blev även injicerad i möss infekterade med streptokocker. Man såg då en långsammare spridning av bakterier i mössen jämfört med då man injicerat en överksam peptidvariant.

I **delarbete IV** har vi studerat antibakteriell verkan hos en del av proteinet kininogen. Även kininogen har en viktig roll vid inflammation, men också vid aktivering av blodkoagulationen vid sårsläkning. Den del av kininogen som vi studerat kallas domän 5 (D5) och är sedan tidigare känd för att kunna binda till

heparin. Vi har i detta delarbete visat att hela D5 (ca 130 aminosyror) har förmåga att döda bakterier. För att vidare kartlägga var i proteinet den antimikrobiella effekten av D5 finns så har vi i bakterieförsök testat korta syntetiska peptider längs med D5 molekyl. Det visade sig vara den senare delen och den mest positivt laddade biten av D5 som har den bakteriedödande verkan. Vidare tittade vi lite närmare på den mest verksamma av de syntetiska peptiderna, HKH20. Den var både heparinbindande och hade en antibakteriell effekt mot alla de tre bakterietyper vi testade. Bäst effekt hade peptiden mot pseudomonasbakterier, då endast ytterst låga koncentrationer av peptiden behövdes för att döda mer än 90 % av bakterierna, på endast 5 minuter. På bilden nedan visas pseudomonasbakterier som blivit behandlade med HKH20 i två olika koncentrationer. Viktigt är också att HKH20 visade sig vara okänslig mot nedbrytning av de bakterieproteiner som vi tidigare sett bryta ner andra antimikrobiella peptider t.ex. LL-37 (delarbete I). Vi har också med olika metoder studerat HKH20s verkan på mänskliga celler. Trots att HKH20 är effektiv för att döda bakterier så verkar peptiden vara ofarlig för våra mänskliga celler. Detta gör peptiden intressant för fortsatt forskning i jakten på bra antimikrobiella peptider som verksamma ämnen i nya antibakteriella läkemedel.



Bilder av *Pseudomonas aeruginosa* bakterier tagna med elektronmikroskop. Obehandlade bakterier (vänster), samt bakterier behandlade med olika koncentrationer av HKH20 (mitten och höger).





## ACKNOWLEDGEMENTS

This thesis would never have been completed without help from many people. I would like to express my sincere gratitude and appreciation to:

**Anna Hultgårdh**, my mentor during the years as a PhD-student and who has become a close friend. You alone gave me the strength and courage to continue the work with my thesis after Isas death. All long talks during lunches were invaluable in my attempts to find ways to go on with my life. As you often told me, Isa will always be my oldest adorable daughter. That is something I know for sure and that will never change. I would also like to thank you for giving me the opportunity to write the start of my book at your department. It meant very much to me.

**Artur Schmidtchen**, my supervisor, for accepting me as a PhD-student. I am fascinated by your enthusiasm and devotion to science and your never ceasing energy in reaching for and achieving goals. It has been both enlightening and stimulating to be a part of your research group.

All people in our group at BMC B14! **Victoria Rydengård**, for being a good companion in the laboratory and at several conferences, but most of all for being such a good friend who always gave me strength and support when I needed it most. **Camilla Larsson**, **Marie-Louise Andersson**, **Andreas Sonesson** for becoming good friends. **Mina Davoudi** for your expert help in the laboratory and for many visits and concern when we were staying at the Children's Hospital. **Katarina Lundqvist** for all the beautiful *Allium giganteum* that are flowering in Isa's corner in our garden during summer. A special thanks also to **Wioletta Baranska-Rybak**, **Mukesh Pasupuleti**, **Praveen Papareddy** and **Ewa Chrostek**.

All co-workers and co-authors in the published papers for your brilliant scientific work.

**Lars Björck**, my co-supervisor, for bringing about a good working atmosphere with much laughter at BMC B14, Lund. All people in the Lars Björck group and especially **Anita Berglund**, for all your help with administrative things and for being such a warm and caring person.

**Arne Egesten** for being an excellent co-supervisor during the LL-37 and LBP projects at UMAS, Malmö.

**Aftab Jasir** and **Claës Schalén** for introducing me into the exciting world of medical research in general and to the field of antibiotic resistance in particular.

**Mikael Bodelsson, Mattias Collin, Arne Egesten, Inga-Maria Frick, Heiko Herwald, Matthias Mörgelin, Magnus Rasmussen, Oonagh Shannon, Ole Sørensen, Hans Tapper, Bo Åkerström**, and all people in your groups for bringing about a joyful environment. **Susanne Bauer**, for our many philosophic talks during our time together at BMC. A special thanks to **Oonagh Shannon** for the proofreading of this book and to **Maria Baumgarten** for expert help in obtaining beautiful EM pictures, and to **Cristina Ciornei, Ingrid Berkestedt, Tobba Sigurdardottir, Axel Nelson** and **Pia Andersson** for being good companions in the laboratory and your sincere concern when Isa got ill. And of course to all the other great people at BMC B14 for making the coffee breaks the highlights of the day.

**Eva Jönsson** for reminding me of, and helping me with, all papers that has to be filled in at different occasions.

**Johanna** and **Pål Jacob Bodin** for being the very best of friends, in both happiness and sorrow and your ability to make life experiences a little easier to carry. **Annika Olsson** and **Erik Zackrisson** and your wonderful girls, **Sara** and **Hanna**, for your perception of life and for becoming such close friends. **Jeanette** and **Erik Nilsson**

for your expert help in candle-wrapping. What would we have done without your help?

My parents **Inger** and **Ulf Andersson** for always being there with support, interest and care. My sister **Maria** and your family **Fredrik, Alice** and **Oscar** for reminding me of the complexity of life and that science cannot explain everything in our world.

**Stellan**, my husband, life-companion and best friend, for all your love, support and for always believing in me. I am also grateful for your expert help with interesting computer challenges during the work of my thesis. I love you always!!

**Isa** and **Alvin**, my wonderful children, for giving me strength, spirit and joy when I need it most. I love you both so very much! I would like to express my deepest gratitude to my little angel Isa for all support and guard of our family. You are always close and you keep reminding me of what is really important in life.



---

**REFERENCES**

1. Mattick, A.T.R., A. Hirsch, and N.J. Berridge. (1947) Further observations on an inhibitory substance (nisin) from lactic streptococci. *Lancet* **250**, 5-8.
2. Hirsch, J.G. (1956) Phagocytin: a bactericidal substance from polymorphonuclear leucocytes. *J Exp Med* **103**, 589-611.
3. Hirsch, J.G. (1956) Studies of the bactericidal action of phagocytin. *J Exp Med* **103**, 613-21.
4. Zeya, H.I. and J.K. Spitznagel. (1963) Antibacterial and Enzymic Basic Proteins from Leukocyte Lysosomes: Separation and Identification. *Science* **142**, 1085-7.
5. Zeya, H.I. and J.K. Spitznagel. (1966) Cationic proteins of polymorphonuclear leukocyte lysosomes. II. Composition, properties, and mechanism of antibacterial action. *J Bacteriol* **91**, 755-62.
6. Zeya, H.I. and J.K. Spitznagel. (1966) Cationic proteins of polymorphonuclear leukocyte lysosomes. I. Resolution of antibacterial and enzymatic activities. *J Bacteriol* **91**, 750-4.
7. Selsted, M.E., D. Szklarek, and R.I. Lehrer. (1984) Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes. *Infect Immun* **45**, 150-4.
8. Weiss, J., R.C. Franson, S. Beckerdite, K. Schmeidler, and P. Elsbach. (1975) Partial characterization and purification of a rabbit granulocyte factor that increases permeability of *Escherichia coli*. *J Clin Invest* **55**, 33-42.
9. Odeberg, H. and I. Olsson. (1975) Antibacterial activity of cationic proteins from human granulocytes. *J Clin Invest* **56**, 1118-24.
10. Ganz, T., M.E. Selsted, D. Szklarek, S.S. Harwig, K. Daher, *et al.* (1985) Defensins. Natural peptide antibiotics of human neutrophils. *J Clin Invest* **76**, 1427-35.
11. Steiner, H., D. Hultmark, Å. Engström, H. Bennich, and H.G. Boman. (1981) Sequence and specificity of two antibacterial proteins involved in insect immunity. *Nature* **292**, 246-8.
12. Zasloff, M. (1987) Magainins, a class of antimicrobial peptides from *Xenopus* skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. *Proc Natl Acad Sci U S A* **84**, 5449-53.
13. Boman, H.G. (2000) Innate immunity and the normal microflora. *Immunol Rev* **173**, 5-16.
14. Lehrer, R.I. and T. Ganz. (1999) Antimicrobial peptides in mammalian and insect host defence. *Curr Opin Immunol* **11**, 23-7.
15. Selsted, M.E. and A.J. Ouellette. (1995) Defensins in granules of phagocytic and non-phagocytic cells. *Trends Cell Biol* **5**, 114-119.
16. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. *Nature* **415**, 389-95.

17. Selsted, M.E. and A.J. Ouellette. (2005) Mammalian defensins in the antimicrobial immune response. *Nat Immunol* **6**, 551-7.
18. Niyonsaba, F. and H. Ogawa. (2005) Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. *J Dermatol Sci* **40**, 157-68.
19. Wickett, R.R. and M.O. Visscher. (2006) Structure and function of the epidermal barrier. *Am J Infect Control* **34**, S98-S110.
20. Fuchs, E. (2007) Scratching the surface of skin development. *Nature* **445**, 834-42.
21. Harding, C.R. (2004) The stratum corneum: structure and function in health and disease. *Dermatol Ther* **17 Suppl 1**, 6-15.
22. Oren, A., T. Ganz, L. Liu, and T. Meerloo. (2003) In human epidermis, beta-defensin 2 is packaged in lamellar bodies. *Exp Mol Pathol* **74**, 180-2.
23. Sorrell, J.M. and A.I. Caplan. (2004) Fibroblast heterogeneity: more than skin deep. *J Cell Sci* **117**, 667-75.
24. Schmidtchen, A., I.M. Frick, and L. Björck. (2001) Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin. *Mol Microbiol* **39**, 708-13.
25. Schmidtchen, A., I.M. Frick, E. Andersson, H. Tapper, and L. Björck. (2002) Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Mol Microbiol* **46**, 157-68.
26. Singer, A.J. and R.A. Clark. (1999) Cutaneous wound healing. *N Engl J Med* **341**, 738-46.
27. Martin, P. and S.J. Leibovich. (2005) Inflammatory cells during wound repair: the good, the bad and the ugly. *Trends Cell Biol* **15**, 599-607.
28. Lorenz, H.P. and M.T. Longaker. (2003) Wounds: Biology, Pathology, and Management. Stanford, CA: Stanford University Medical Center. 77-88.
29. Falanga, V. (2005) Wound healing and its impairment in the diabetic foot. *Lancet* **366**, 1736-43.
30. Hinz, B. (2006) Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. *Eur J Cell Biol* **85**, 175-81.
31. Levenson, S.M., E.F. Geever, L.V. Crowley, J.F. Oates, 3rd, C.W. Berard, *et al.* (1965) The Healing of Rat Skin Wounds. *Ann Surg* **161**, 293-308.
32. Hancock, R.E. and G. Diamond. (2000) The role of cationic antimicrobial peptides in innate host defences. *Trends Microbiol* **8**, 402-10.
33. Agrawal, A., Q.M. Eastman, and D.G. Schatz. (1998) Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. *Nature* **394**, 744-51.
34. Mörner, K.A.H. (1908) The Nobel Prize in Physiology or Medicine 1908- Presentation Speech: From Nobel Lectures, Physiology or Medicine 1901-1921, Elsevier Publishing Company, Amsterdam, 1967.

35. Nordahl, E.A., V. Rydengård, P. Nyberg, D.P. Nitsche, M. Mörgelin, *et al.* (2004) Activation of the complement system generates antibacterial peptides. *Proc Natl Acad Sci U S A* **101**, 16879-84.
  36. Janeway, C.A., Jr. (2001) How the immune system works to protect the host from infection: a personal view. *Proc Natl Acad Sci U S A* **98**, 7461-8.
  37. Metchnikov, E. (1884) Über eine sprosspilzkrankheit der daphnien. Beitrag zur lehre über den kampf der phagozyten gegen krankheitserreger. *Virchows Arch* **96**, 177-195.
  38. Medzhitov, R. and C. Janeway, Jr. (2000) Innate immune recognition: mechanisms and pathways. *Immunol Rev* **173**, 89-97.
  39. Liu, L., A.A. Roberts, and T. Ganz. (2003) By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. *J Immunol* **170**, 575-80.
  40. Medzhitov, R. and C. Janeway, Jr. (2000) The Toll receptor family and microbial recognition. *Trends Microbiol* **8**, 452-6.
  41. Purcell, M.K., K.D. Smith, L. Hood, J.R. Winton, and J.C. Roach. (2006) Conservation of Toll-Like Receptor Signaling Pathways in Teleost Fish. *Comp Biochem Physiol Part D Genomics Proteomics* **1**, 77-88.
  42. Roach, J.C., G. Glusman, L. Rowen, A. Kaur, M.K. Purcell, *et al.* (2005) The evolution of vertebrate Toll-like receptors. *Proc Natl Acad Sci U S A* **102**, 9577-82.
  43. Lemaitre, B., E. Nicolas, L. Michaut, J.M. Reichhart, and J.A. Hoffmann. (1996) The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in *Drosophila* adults. *Cell* **86**, 973-83.
  44. Hultmark, D. (2003) *Drosophila* immunity: paths and patterns. *Curr Opin Immunol* **15**, 12-9.
  45. Rus, H., C. Cudrici, and F. Niculescu. (2005) The role of the complement system in innate immunity. *Immunol Res* **33**, 103-12.
  46. Colten, H.R., R.C. Strunk, D.H. Perlmuter, and F.S. Cole. (1986) Regulation of complement protein biosynthesis in mononuclear phagocytes. *Ciba Found Symp* **118**, 141-54.
  47. Pasch, M.C., N.H. Van Den Bosch, M.R. Daha, J.D. Bos, and S.S. Asghar. (2000) Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. *J Invest Dermatol* **114**, 78-82.
  48. Stöve, S., T. Welte, T.O. Wagner, A. Kola, A. Klos, *et al.* (1996) Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. *Clin Diagn Lab Immunol* **3**, 175-83.
  49. Narkio-Makela, M., A.M. Teppo, and S. Meri. (2000) Complement C3 cleavage and cytokines interleukin-1beta and tumor necrosis factor-alpha in otitis media with effusion. *Laryngoscope* **110**, 1745-9.
  50. Hugli, T.E. (1990) Structure and function of C3a anaphylatoxin. *Curr Top Microbiol Immunol* **153**, 181-208.
-



51. Pasupuleti, M., B. Walse, E.A. Nordahl, M. Mörgelin, M. Malmsten, *et al.* (2007) Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. *J Biol Chem* **282**, 2520-8.
52. Sonesson, A., L. Ringstad, E.A. Nordahl, M. Malmsten, M. Mörgelin, *et al.* (2007) Antifungal activity of C3a and C3a-derived peptides against *Candida*. *Biochim Biophys Acta* **1768**, 346-53.
53. Lu, Z.X., K.F. Fok, B.W. Erickson, and T.E. Hugli. (1984) Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide. *J Biol Chem* **259**, 7367-70.
54. Wang, G., X. Li, and Z. Wang. (2009) APD2: the updated antimicrobial peptide database and its application in peptide design. *Nucleic Acids Res* **37**, D933-7.
55. Garcia-Olmedo, F., A. Molina, J.M. Alamillo, and P. Rodriguez-Palenzuela. (1998) Plant defense peptides. *Biopolymers* **47**, 479-91.
56. Kurata, S. (2006) Recognition and elimination of diversified pathogens in insect defense systems. *Mol Divers* **10**, 599-605.
57. Rinaldi, A.C. (2002) Antimicrobial peptides from amphibian skin: an expanding scenario. *Curr Opin Chem Biol* **6**, 799-804.
58. Shi, J. and A.C. Camus. (2006) Hepcidins in amphibians and fishes: Antimicrobial peptides or iron-regulatory hormones? *Dev Comp Immunol* **30**, 746-55.
59. Sugiarto, H. and P.L. Yu. (2004) Avian antimicrobial peptides: the defense role of beta-defensins. *Biochem Biophys Res Commun* **323**, 721-7.
60. Levy, O. (2000) Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. *Blood* **96**, 2664-72.
61. Arnold, T.M., G.N. Forrest, and K.J. Messmer. (2007) Polymyxin antibiotics for gram-negative infections. *Am J Health Syst Pharm* **64**, 819-26.
62. Kieffer, A.E., Y. Goumon, O. Ruh, S. Chasserot-Golaz, G. Nullans, *et al.* (2003) The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. *Faseb J* **17**, 776-8.
63. Arrighi, R.B., C. Nakamura, J. Miyake, H. Hurd, and J.G. Burgess. (2002) Design and activity of antimicrobial peptides against sporogonic-stage parasites causing murine malaras. *Antimicrob Agents Chemother* **46**, 2104-10.
64. Robinson, W.E., Jr., B. McDougall, D. Tran, and M.E. Selsted. (1998) Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. *J Leukoc Biol* **63**, 94-100.
65. Tamamura, H., M. Waki, M. Imai, A. Otaka, T. Ibuka, *et al.* (1998) Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure. *Bioorg Med Chem* **6**, 473-9.
66. Cruciani, R.A., J.L. Barker, M. Zasloff, H.C. Chen, and O. Colamonici. (1991) Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. *Proc Natl Acad Sci U S A* **88**, 3792-6.

- 
67. Lindholm, P., U. Göransson, S. Johansson, P. Claesson, J. Gullbo, *et al.* (2002) Cyclotides: a novel type of cytotoxic agents. *Mol Cancer Ther* **1**, 365-9.
  68. Miyasaki, K.T. and R.I. Lehrer. (1998) Beta-sheet antibiotic peptides as potential dental therapeutics. *Int J Antimicrob Agents* **9**, 269-80.
  69. Boman, H.G., I. Faye, G.H. Gudmundsson, J.Y. Lee, and D.A. Lidholm. (1991) Cell-free immunity in *Cecropia*. A model system for antibacterial proteins. *Eur J Biochem* **201**, 23-31.
  70. Hoffmann, J.A., F.C. Kafatos, C.A. Janeway, and R.A. Ezekowitz. (1999) Phylogenetic perspectives in innate immunity. *Science* **284**, 1313-8.
  71. Hancock, R.E. and M.G. Scott. (2000) The role of antimicrobial peptides in animal defenses. *Proc Natl Acad Sci U S A* **97**, 8856-61.
  72. Beisswenger, C. and R. Bals. (2005) Functions of antimicrobial peptides in host defense and immunity. *Curr Protein Pept Sci* **6**, 255-64.
  73. Elsbach, P. (2003) What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? *J Clin Invest* **111**, 1643-5.
  74. Yang, D., A. Biragyn, D.M. Hoover, J. Lubkowski, and J.J. Oppenheim. (2004) Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. *Annu Rev Immunol* **22**, 181-215.
  75. Agerberth, B., J. Charo, J. Werr, B. Olsson, F. Idali, *et al.* (2000) The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. *Blood* **96**, 3086-93.
  76. Yang, D., Q. Chen, A.P. Schmidt, G.M. Anderson, J.M. Wang, *et al.* (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPR1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. *J Exp Med* **192**, 1069-74.
  77. Territo, M.C., T. Ganz, M.E. Selsted, and R. Lehrer. (1989) Monocyte-chemotactic activity of defensins from human neutrophils. *J Clin Invest* **84**, 2017-20.
  78. Koczulla, R., G. Von Degenfeld, C. Kupatt, F. Krotz, S. Zahler, *et al.* (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J Clin Invest* **111**, 1665-1672.
  79. Li, Q.X., H.A. Tang, Y.Z. Li, M. Wang, L.F. Wang, *et al.* (2000) Synthesis, characterization, and antibacterial activity of novel Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes with vitamin K3-thiosemicarbazone. *J Inorg Biochem* **78**, 167-74.
  80. Ciornei, C.D., A. Egesten, and M. Bodelsson. (2003) Effects of human cathelicidin antimicrobial peptide LL-37 on lipopolysaccharide-induced nitric oxide release from rat aorta in vitro. *Acta Anaesthesiol Scand* **47**, 213-20.
  81. Okumura, K., A. Itoh, E. Isogai, K. Hirose, Y. Hosokawa, *et al.* (2004) C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. *Cancer Lett* **212**, 185-94.
-

82. Yoo, Y.C., R. Watanabe, Y. Koike, M. Mitobe, K. Shimazaki, *et al.* (1997) Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. *Biochem Biophys Res Commun* **237**, 624-8.
83. Bowdish, D.M., D.J. Davidson, Y.E. Lau, K. Lee, M.G. Scott, *et al.* (2005) Impact of LL-37 on anti-infective immunity. *J Leukoc Biol* **77**, 451-9.
84. Bowdish, D.M., D.J. Davidson, M.G. Scott, and R.E. Hancock. (2005) Immunomodulatory activities of small host defense peptides. *Antimicrob Agents Chemother* **49**, 1727-32.
85. Mookherjee, N., K.L. Brown, D.M. Bowdish, S. Doria, R. Falsafi, *et al.* (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. *J Immunol* **176**, 2455-64.
86. Mookherjee, N., H.L. Wilson, S. Doria, Y. Popowych, R. Falsafi, *et al.* (2006) Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. *J Leukoc Biol* **80**, 1563-74.
87. Jenssen, H., P. Hamill, and R.E. Hancock. (2006) Peptide antimicrobial agents. *Clin Microbiol Rev* **19**, 491-511.
88. Brown, K.L. and R.E. Hancock. (2006) Cationic host defense (antimicrobial) peptides. *Curr Opin Immunol* **18**, 24-30.
89. Yount, N.Y., A.S. Bayer, Y.Q. Xiong, and M.R. Yeaman. (2006) Advances in antimicrobial peptide immunobiology. *Biopolymers* **84**, 435-58.
90. Eisenberg, D., E. Schwarz, M. Komaromy, and R. Wall. (1984) Analysis of membrane and surface protein sequences with the hydrophobic moment plot. *J Mol Biol* **179**, 125-42.
91. Pallai, P.V., M. Mabilia, M. Goodman, W. Vale, and J. Rivier. (1983) Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: circular dichroism and prediction studies. *Proc Natl Acad Sci U S A* **80**, 6770-4.
92. Park, I.Y., J.H. Cho, K.S. Kim, Y.B. Kim, M.S. Kim, *et al.* (2004) Helix stability confers salt resistance upon helical antimicrobial peptides. *J Biol Chem* **279**, 13896-901.
93. Pasupuleti, M., B. Walse, B. Svensson, M. Malmsten, and A. Schmidtchen. (2008) Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach. *Biochemistry* **47**, 9057-70.
94. Brogden, K.A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol* **3**, 238-50.
95. Oren, Z. and Y. Shai. (1998) Mode of action of linear amphipathic alpha-helical antimicrobial peptides. *Biopolymers* **47**, 451-63.
96. Park, C.B., K.S. Yi, K. Matsuzaki, M.S. Kim, and S.C. Kim. (2000) Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. *Proc Natl Acad Sci U S A* **97**, 8245-50.

- 
97. Andersson, M., A. Boman, and H.G. Boman. (2003) *Ascaris* nematodes from pig and human make three antibacterial peptides: isolation of cecropin P1 and two ASABF peptides. *Cell Mol Life Sci* **60**, 599-606.
  98. Lee, J.Y., A. Boman, C.X. Sun, M. Andersson, H. Jornvall, *et al.* (1989) Antibacterial peptides from pig intestine: isolation of a mammalian cecropin. *Proc Natl Acad Sci U S A* **86**, 9159-62.
  99. Mor, A., V.H. Nguyen, A. Delfour, D. Migliore-Samour, and P. Nicolas. (1991) Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. *Biochemistry* **30**, 8824-30.
  100. Frohm, M., B. Agerberth, G. Ahangari, M. Ståhle-Bäckdahl, S. Liden, *et al.* (1997) The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. *J Biol Chem* **272**, 15258-63.
  101. Johansson, J., G.H. Gudmundsson, M.E. Rottenberg, K.D. Berndt, and B. Agerberth. (1998) Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. *J Biol Chem* **273**, 3718-24.
  102. Ganz, T. (2005) Defensins and other antimicrobial peptides: a historical perspective and an update. *Comb Chem High Throughput Screen* **8**, 209-17.
  103. Yount, N.Y. and M.R. Yeaman. (2004) Multidimensional signatures in antimicrobial peptides. *Proc Natl Acad Sci U S A* **101**, 7363-8.
  104. Kokryakov, V.N., S.S. Harwig, E.A. Panyutich, A.A. Shevchenko, G.M. Aleshina, *et al.* (1993) Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. *FEBS Lett* **327**, 231-6.
  105. Ganz, T. and R.I. Lehrer. (1995) Defensins. *Pharmacol Ther* **66**, 191-205.
  106. Lehrer, R.I. (2004) Primate defensins. *Nat Rev Microbiol* **2**, 727-38.
  107. Tang, Y.Q., J. Yuan, G. Osapay, K. Osapay, D. Tran, *et al.* (1999) A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. *Science* **286**, 498-502.
  108. Cociancich, S., A. Ghazi, C. Hetru, J.A. Hoffmann, and L. Letellier. (1993) Insect defensin, an inducible antibacterial peptide, forms voltage-dependent channels in *Micrococcus luteus*. *J Biol Chem* **268**, 19239-45.
  109. Kavanagh, K. and S. Dowd. (2004) Histatins: antimicrobial peptides with therapeutic potential. *J Pharm Pharmacol* **56**, 285-9.
  110. Gifford, J.L., H.N. Hunter, and H.J. Vogel. (2005) Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. *Cell Mol Life Sci* **62**, 2588-98.
  111. Hoek, K.S., J.M. Milne, P.A. Grieve, D.A. Dionysius, and R. Smith. (1997) Antibacterial activity in bovine lactoferrin-derived peptides. *Antimicrob Agents Chemother* **41**, 54-9.
  112. Zucht, H.D., M. Raida, K. Adermann, H.J. Magert, and W.G. Forssmann. (1995) Casocidin-I: a casein-alpha s2 derived peptide exhibits antibacterial activity. *FEBS Lett* **372**, 185-8.
-

113. Mak, P., K. Wojcik, J. Silberring, and A. Dubin. (2000) Antimicrobial peptides derived from heme-containing proteins: hemocidins. *Antonie Van Leeuwenhoek* **77**, 197-207.
114. Dubin, A., P. Mak, G. Dubin, M. Rzychon, J. Stec-Niemczyk, *et al.* (2005) New generation of peptide antibiotics. *Acta Biochim Pol* **52**, 633-8.
115. Frick, I.M., P. Åkesson, H. Herwald, M. Mörgelin, M. Malmsten, *et al.* (2006) The contact system--a novel branch of innate immunity generating antibacterial peptides. *Embo J* **25**, 5569-78.
116. Nordahl, E.A., V. Rydengård, M. Mörgelin, and A. Schmidtchen. (2005) Domain 5 of high molecular weight kininogen is antibacterial. *J Biol Chem* **280**, 34832-9.
117. Andersson, E., V. Rydengård, A. Sonesson, M. Mörgelin, L. Björck, *et al.* (2004) Antimicrobial activities of heparin-binding peptides. *Eur J Biochem* **271**, 1219-26.
118. Edström, A.M., J. Malm, B. Frohm, J.A. Martellini, A. Giwercman, *et al.* (2008) The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins. *J Immunol* **181**, 3413-21.
119. Brogden, K.A., A.J. De Lucca, J. Bland, and S. Elliott. (1996) Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for *Pasteurella haemolytica*. *Proc Natl Acad Sci U S A* **93**, 412-6.
120. Lai, R., H. Liu, W. Hui Lee, and Y. Zhang. (2002) An anionic antimicrobial peptide from toad *Bombina maxima*. *Biochem Biophys Res Commun* **295**, 796-9.
121. Schitteck, B., R. Hipfel, B. Sauer, J. Bauer, H. Kalbacher, *et al.* (2001) Dermcidin: a novel human antibiotic peptide secreted by sweat glands. *Nat Immunol* **2**, 1133-7.
122. Hancock, R.E., K.L. Brown, and N. Mookherjee. (2006) Host defence peptides from invertebrates--emerging antimicrobial strategies. *Immunobiology* **211**, 315-22.
123. Bals, R. and J.M. Wilson. (2003) Cathelicidins--a family of multifunctional antimicrobial peptides. *Cell Mol Life Sci* **60**, 711-20.
124. Sørensen, O., K. Arnljots, J.B. Cowland, D.F. Bainton, and N. Borregaard. (1997) The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. *Blood* **90**, 2796-803.
125. Rivas-Santiago, B., R. Hernandez-Pando, C. Carranza, E. Juarez, J.L. Contreras, *et al.* (2008) Expression of cathelicidin LL-37 during *Mycobacterium tuberculosis* infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. *Infect Immun* **76**, 935-41.
126. Bals, R., X. Wang, M. Zasloff, and J.M. Wilson. (1998) The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. *Proc Natl Acad Sci U S A* **95**, 9541-6.
127. Uzzell, T., E.D. Stolzenberg, A.E. Shinnar, and M. Zasloff. (2003) Hagfish intestinal antimicrobial peptides are ancient cathelicidins. *Peptides* **24**, 1655-67.
128. Xiao, Y., Y. Cai, Y.R. Bommineni, S.C. Fernando, O. Praphash, *et al.* (2006) Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity. *J Biol Chem* **281**, 2858-67.

- 
129. Gudmundsson, G.H., B. Agerberth, J. Odeberg, T. Bergman, B. Olsson, *et al.* (1996) The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. *Eur J Biochem* **238**, 325-32.
  130. Sørensen, O., J.B. Cowland, J. Askaa, and N. Borregaard. (1997) An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. *J Immunol Methods* **206**, 53-9.
  131. Sørensen, O.E., P. Follin, A.H. Johnsen, J. Calafat, G.S. Tjabringa, *et al.* (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood* **97**, 3951-9.
  132. Malm, J., O. Sørensen, T. Persson, M. Frohm-Nilsson, B. Johansson, *et al.* (2000) The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. *Infect Immun* **68**, 4297-302.
  133. Sørensen, O.E., L. Gram, A.H. Johnsen, E. Andersson, S. Bangsboll, *et al.* (2003) Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. *J Biol Chem* **278**, 28540-6.
  134. Tjabringa, G.S., D.K. Ninaber, J.W. Drijfhout, K.F. Rabe, and P.S. Hiemstra. (2006) Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. *Int Arch Allergy Immunol* **140**, 103-12.
  135. Elssner, A., M. Duncan, M. Gavrilin, and M.D. Wewers. (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. *J Immunol* **172**, 4987-94.
  136. Bergman, P., L. Walter-Jallow, K. Broliden, B. Agerberth, and J. Söderlund. (2007) The antimicrobial peptide LL-37 inhibits HIV-1 replication. *Curr HIV Res* **5**, 410-5.
  137. Selsted, M.E., Y.Q. Tang, W.L. Morris, P.A. McGuire, M.J. Novotny, *et al.* (1993) Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. *J Biol Chem* **268**, 6641-8.
  138. Wu, Z., D.M. Hoover, D. Yang, C. Boulegue, F. Santamaria, *et al.* (2003) Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. *Proc Natl Acad Sci U S A* **100**, 8880-5.
  139. Linzmeier, R., C.H. Ho, B.V. Hoang, and T. Ganz. (1999) A 450-kb contig of defensin genes on human chromosome 8p23. *Gene* **233**, 205-11.
  140. Lehrer, R.I. and T. Ganz. (2002) Defensins of vertebrate animals. *Curr Opin Immunol* **14**, 96-102.
  141. Ganz, T., M.E. Selsted, and R.I. Lehrer. (1990) Defensins. *Eur J Haematol* **44**, 1-8.
  142. Mackewicz, C.E., J. Yuan, P. Tran, L. Diaz, E. Mack, *et al.* (2003) alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. *Aids* **17**, F23-32.
  143. Chalifour, A., P. Jeannin, J.F. Gauchat, A. Blaecke, M. Malissard, *et al.* (2004) Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. *Blood* **104**, 1778-83.
  144. Ouellette, A.J. and C.L. Bevins. (2001) Paneth cell defensins and innate immunity of the small bowel. *Inflamm Bowel Dis* **7**, 43-50.
-

145. Ghosh, D., E. Porter, B. Shen, S.K. Lee, D. Wilk, *et al.* (2002) Paneth cell trypsin is the processing enzyme for human defensin-5. *Nat Immunol* **3**, 583-90.
146. Quayle, A.J., E.M. Porter, A.A. Nussbaum, Y.M. Wang, C. Brabec, *et al.* (1998) Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. *Am J Pathol* **152**, 1247-58.
147. Schutte, B.C. and P.B. McCray, Jr. (2002) [beta]-defensins in lung host defense. *Annu Rev Physiol* **64**, 709-48.
148. Schutte, B.C., J.P. Mitros, J.A. Bartlett, J.D. Walters, H.P. Jia, *et al.* (2002) Discovery of five conserved beta -defensin gene clusters using a computational search strategy. *Proc Natl Acad Sci U S A* **99**, 2129-33.
149. Bensch, K.W., M. Raida, H.J. Magert, P. Schulz-Knappe, and W.G. Forssmann. (1995) hBD-1: a novel beta-defensin from human plasma. *FEBS Lett* **368**, 331-5.
150. De Smet, K. and R. Contreras. (2005) Human antimicrobial peptides: defensins, cathelicidins and histatins. *Biotechnol Lett* **27**, 1337-47.
151. Garcia, J.R., A. Krause, S. Schulz, F.J. Rodriguez-Jimenez, E. Kluver, *et al.* (2001) Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. *Faseb J* **15**, 1819-21.
152. Yamaguchi, Y., T. Nagase, R. Makita, S. Fukuhara, T. Tomita, *et al.* (2002) Identification of multiple novel epididymis-specific beta-defensin isoforms in humans and mice. *J Immunol* **169**, 2516-23.
153. Schneider, J.J., A. Unholzer, M. Schaller, M. Schafer-Korting, and H.C. Korting. (2005) Human defensins. *J Mol Med* **83**, 587-95.
154. Nguyen, T.X., A.M. Cole, and R.I. Lehrer. (2003) Evolution of primate theta-defensins: a serpentine path to a sweet tooth. *Peptides* **24**, 1647-54.
155. Ganz, T. and R.I. Lehrer. (1998) Antimicrobial peptides of vertebrates. *Current Opinion in Immunology* **10**, 41-44.
156. Gennaro, R., M. Zanetti, M. Benincasa, E. Podda, and M. Miani. (2002) Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. *Curr Pharm Des* **8**, 763-78.
157. Hancock, R.E. and A. Rozek. (2002) Role of membranes in the activities of antimicrobial cationic peptides. *FEMS Microbiol Lett* **206**, 143-9.
158. Wade, D., A. Boman, B. Wahlin, C.M. Drain, D. Andreu, *et al.* (1990) All-D amino acid-containing channel-forming antibiotic peptides. *Proc Natl Acad Sci U S A* **87**, 4761-5.
159. Chen, F.Y., M.T. Lee, and H.W. Huang. (2003) Evidence for membrane thinning effect as the mechanism for peptide-induced pore formation. *Biophys J* **84**, 3751-8.
160. Bechinger, B. (1999) The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. *Biochim Biophys Acta* **1462**, 157-83.

- 
161. Wu, M., E. Maier, R. Benz, and R.E. Hancock. (1999) Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of *Escherichia coli*. *Biochemistry* **38**, 7235-42.
  162. Shai, Y. (1999) Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. *Biochim Biophys Acta* **1462**, 55-70.
  163. Ladokhin, A.S. and S.H. White. (2001) 'Detergent-like' permeabilization of anionic lipid vesicles by melittin. *Biochim Biophys Acta* **1514**, 253-60.
  164. Pouny, Y., D. Rapaport, A. Mor, P. Nicolas, and Y. Shai. (1992) Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. *Biochemistry* **31**, 12416-23.
  165. Shai, Y. (1995) Molecular recognition between membrane-spanning polypeptides. *Trends Biochem Sci* **20**, 460-4.
  166. Naito, A., T. Nagao, K. Norisada, T. Mizuno, S. Tuzi, *et al.* (2000) Conformation and dynamics of melittin bound to magnetically oriented lipid bilayers by solid-state (31)P and (13)C NMR spectroscopy. *Biophys J* **78**, 2405-17.
  167. Mousli, M., J.L. Bueb, C. Bronner, B. Rouot, and Y. Landry. (1990) G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. *Trends Pharmacol Sci* **11**, 358-62.
  168. Perez-Paya, E., R.A. Houghten, and S.E. Blondelle. (1994) Determination of the secondary structure of selected melittin analogues with different haemolytic activities. *Biochem J* **299 ( Pt 2)**, 587-91.
  169. Rinaldi, A.C., M.L. Mangoni, A. Rufo, C. Luzi, D. Barra, *et al.* (2002) Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. *Biochem J* **368**, 91-100.
  170. Wiegand, I., K. Hilpert, and R.E. Hancock. (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat Protoc* **3**, 163-75.
  171. Elion, G.B., S. Singer, and G.H. Hitchings. (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. *J Biol Chem* **208**, 477-88.
  172. Matsuzaki, K., Y. Mitani, K.Y. Akada, O. Murase, S. Yoneyama, *et al.* (1998) Mechanism of synergism between antimicrobial peptides magainin 2 and PGLa. *Biochemistry* **37**, 15144-53.
  173. McCafferty, D.G., P. Cudic, M.K. Yu, D.C. Behenna, and R. Kruger. (1999) Synergy and duality in peptide antibiotic mechanisms. *Curr Opin Chem Biol* **3**, 672-80.
  174. Peschel, A. and L.V. Collins. (2001) Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. *Peptides* **22**, 1651-9.
  175. Nizet, V. (2006) Antimicrobial peptide resistance mechanisms of human bacterial pathogens. *Curr Issues Mol Biol* **8**, 11-26.
-



176. Jin, T., M. Bokarewa, T. Foster, J. Mitchell, J. Higgins, *et al.* (2004) Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. *J Immunol* **172**, 1169-76.
177. Sieprawska-Lupa, M., P. Mydel, K. Krawczyk, K. Wojcik, M. Puklo, *et al.* (2004) Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. *Antimicrob Agents Chemother* **48**, 4673-9.
178. Ulvatne, H., H.H. Haukland, O. Samuelson, M. Kramer, and L.H. Vorland. (2002) Proteases in Escherichia coli and Staphylococcus aureus confer reduced susceptibility to lactoferrin B. *J Antimicrob Chemother* **50**, 461-7.
179. Fleming, A. (1922) On a remarkable bacteriolytic element found in tissues and secretions. *Proc R Soc Lond B Biol Sci* **93**, 306-317.
180. Ganz, T. (2004) Antimicrobial polypeptides. *J Leukoc Biol* **75**, 34-8.
181. Weinberg, E.D. (2007) Antibiotic properties and applications of lactoferrin. *Curr Pharm Des* **13**, 801-2.
182. Shafer, W.M., V.C. Onunka, and L.E. Martin. (1986) Antigonococcal activity of human neutrophil cathepsin G. *Infect Immun* **54**, 184-8.
183. Rydengård, V., A.K. Olsson, M. Mörgelin, and A. Schmidtchen. (2007) Histidine-rich glycoprotein exerts antibacterial activity. *FEBS J* **274**, 377-89.
184. Ooi, C.E., J. Weiss, P. Elsbach, B. Frangione, and B. Mannion. (1987) A 25-kDa NH<sub>2</sub>-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. *J Biol Chem* **262**, 14891-4.
185. Rydengård, V., O. Shannon, K. Lundqvist, L. Kacprzyk, A. Chalupka, *et al.* (2008) Histidine-rich glycoprotein protects from systemic Candida infection. *PLoS Pathog* **4**, e1000116.
186. Brogden, K.A., J.M. Guthmiller, M. Salzet, and M. Zasloff. (2005) The nervous system and innate immunity: the neuropeptide connection. *Nat Immunol* **6**, 558-64.
187. Kowalska, K., D.B. Carr, and A.W. Lipkowski. (2002) Direct antimicrobial properties of substance P. *Life Sci* **71**, 747-50.
188. Vouldoukis, I., Y. Shai, P. Nicolas, and A. Mor. (1996) Broad spectrum antibiotic activity of the skin-PYY. *FEBS Lett* **380**, 237-40.
189. Mor, A., M. Amiche, and P. Nicolas. (1994) Structure, synthesis, and activity of dermaseptin b, a novel vertebrate defensive peptide from frog skin: relationship with adenoregulin. *Biochemistry* **33**, 6642-50.
190. Cole, A.M., J. Shi, A. Ceccarelli, Y.H. Kim, A. Park, *et al.* (2001) Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. *Blood* **97**, 297-304.
191. Yang, D., Q. Chen, D.M. Hoover, P. Staley, K.D. Tucker, *et al.* (2003) Many chemokines including CCL20/MIP-3 $\alpha$  display antimicrobial activity. *J Leukoc Biol* **74**, 448-55.

192. Malmsten, M., M. Davoudi, B. Walse, V. Rydengård, M. Pasupuleti, *et al.* (2007) Antimicrobial peptides derived from growth factors. *Growth Factors* **25**, 60-70.
  193. Kim, H.S., H. Yoon, I. Minn, C.B. Park, W.T. Lee, *et al.* (2000) Pepsin-mediated processing of the cytoplasmic histone H2A to strong antimicrobial peptide buforin I. *J Immunol* **165**, 3268-74.
  194. Harder, J. and J.M. Schröder. (2005) Antimicrobial peptides in human skin. *Chem Immunol Allergy* **86**, 22-41.
  195. Schröder, J.M. and J. Harder. (2006) Antimicrobial skin peptides and proteins. *Cell Mol Life Sci* **63**, 469-86.
  196. Harder, J. and J.M. Schröder. (2002) RNase 7, a Novel Innate Immune Defense Antimicrobial Protein of Healthy Human Skin. *J Biol Chem* **277**, 46779-84.
  197. Rieg, S., C. Garbe, B. Sauer, H. Kalbacher, and B. Schittek. (2004) Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. *Br J Dermatol* **151**, 534-9.
  198. Baechle, D., T. Flad, A. Cansier, H. Steffen, B. Schittek, *et al.* (2006) Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. *J Biol Chem* **281**, 5406-15.
  199. Murakami, M., T. Ohtake, R.A. Dorschner, B. Schittek, C. Garbe, *et al.* (2002) Cathelicidin anti-microbial Peptide expression in sweat, an innate defense system for the skin. *J Invest Dermatol* **119**, 1090-5.
  200. Murakami, M., B. Lopez-Garcia, M. Braff, R.A. Dorschner, and R.L. Gallo. (2004) Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. *J Immunol* **172**, 3070-7.
  201. Yamasaki, K., J. Schaubert, A. Coda, H. Lin, R.A. Dorschner, *et al.* (2006) Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. *Faseb J* **20**, 2068-80.
  202. Sørensen, O.E., D.R. Thapa, A. Rosenthal, L. Liu, A.A. Roberts, *et al.* (2005) Differential regulation of beta-defensin expression in human skin by microbial stimuli. *J Immunol* **174**, 4870-9.
  203. Sørensen, O.E., J.B. Cowland, K. Theilgaard-Monch, L. Liu, T. Ganz, *et al.* (2003) Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. *J Immunol* **170**, 5583-9.
  204. Sørensen, O.E., D.R. Thapa, K.M. Roupé, E.V. Valore, U. Sjöbring, *et al.* (2006) Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. *J Clin Invest* **116**, 1878-85.
  205. Gläser, R., J. Harder, H. Lange, J. Bartels, E. Christophers, *et al.* (2005) Antimicrobial psoriasin (S100A7) protects human skin from *Escherichia coli* infection. *Nat Immunol* **6**, 57-64.
  206. Wang, T.T., F.P. Nestel, V. Bourdeau, Y. Nagai, Q. Wang, *et al.* (2004) Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol* **173**, 2909-12.
-

207. Weber, G., J.D. Heilborn, C.I. Chamorro Jimenez, A. Hammarsjö, H. Törmä, *et al.* (2005) Vitamin D induces the antimicrobial protein hCAP18 in human skin. *J Invest Dermatol* **124**, 1080-2.
208. Turner, J., Y. Cho, N.N. Dinh, A.J. Waring, and R.I. Lehrer. (1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. *Antimicrob Agents Chemother* **42**, 2206-14.
209. Di Nardo, A., A. Vitiello, and R.L. Gallo. (2003) Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. *J Immunol* **170**, 2274-8.
210. Riordan, J.R. (1993) The cystic fibrosis transmembrane conductance regulator. *Annu Rev Physiol* **55**, 609-30.
211. Smith, J.J., S.M. Travis, E.P. Greenberg, and M.J. Welsh. (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. *Cell* **85**, 229-36.
212. Goldman, M.J., G.M. Anderson, E.D. Stolzenberg, U.P. Kari, M. Zasloff, *et al.* (1997) Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. *Cell* **88**, 553-60.
213. Taggart, C.C., C.M. Greene, S.G. Smith, R.L. Levine, P.B. McCray, Jr., *et al.* (2003) Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. *J Immunol* **171**, 931-7.
214. Bucki, R., F.J. Byfield, and P.A. Janmey. (2007) Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. *Eur Respir J* **29**, 624-32.
215. Ganz, T., J.A. Metcalf, J.I. Gallin, L.A. Boxer, and R.I. Lehrer. (1988) Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. *J Clin Invest* **82**, 552-6.
216. Pütsep, K., G. Carlsson, H.G. Boman, and M. Andersson. (2002) Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. *Lancet* **360**, 1144-9.
217. Howell, M.D., N. Novak, T. Bieber, S. Pastore, G. Girolomoni, *et al.* (2005) Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. *J Invest Dermatol* **125**, 738-45.
218. Ong, P.Y., T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, *et al.* (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* **347**, 1151-60.
219. Harder, J. and J.M. Schröder. (2005) Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. *J Leukoc Biol* **77**, 476-86.
220. Christophers, E. and T. Henseler. (1987) Contrasting disease patterns in psoriasis and atopic dermatitis. *Arch Dermatol Res* **279 Suppl**, S48-51.
221. Lande, R., J. Gregorio, V. Facchinetti, B. Chatterjee, Y.H. Wang, *et al.* (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. *Nature* **449**, 564-9.

222. Lynn, D.J., G.L. Winsor, C. Chan, N. Richard, M.R. Laird, *et al.* (2008) InnateDB: facilitating systems-level analyses of the mammalian innate immune response. *Mol Syst Biol* **4**, 218.
223. Mygind, P.H., R.L. Fischer, K.M. Schnorr, M.T. Hansen, C.P. Sonksen, *et al.* (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. *Nature* **437**, 975-80.
224. Isaacson, R.E. (2003) MBI-226. Micrologix/Fujisawa. *Curr Opin Investig Drugs* **4**, 999-1003.
225. Oren, Z., J.C. Lerman, G.H. Gudmundsson, B. Agerberth, and Y. Shai. (1999) Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. *Biochem J* **341 ( Pt 3)**, 501-13.
226. de Kreijl, A., G. Venema, and B. van den Burg. (2000) Substrate specificity in the highly heterogeneous M4 peptidase family is determined by a small subset of amino acids. *J Biol Chem* **275**, 31115-20.
227. Cardin, A.D. and H.J. Weintraub. (1989) Molecular modeling of protein-glycosaminoglycan interactions. *Arteriosclerosis* **9**, 21-32.
228. Pixley, R.A., Y. Lin, I. Isordia-Salas, and R.W. Colman. (2003) Fine mapping of the sequences in domain 5 of high molecular weight kininogen (HK) interacting with heparin and zinc. *J Thromb Haemost* **1**, 1791-8.
229. Weisel, J.W., C. Nagaswami, J.L. Woodhead, R.A. DeLa Cadena, J.D. Page, *et al.* (1994) The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. *J Biol Chem* **269**, 10100-6.
230. Sørensen, O.E., N. Borregaard, and A.M. Cole. (2008) Antimicrobial peptides in innate immune responses. *Contrib Microbiol* **15**, 61-77.
231. Amara, U., D. Rittirsch, M. Flierl, U. Brückner, A. Klos, *et al.* (2008) Interaction between the coagulation and complement system. *Adv Exp Med Biol* **632**, 71-9.

